nitrates has been researched along with Heart Failure in 337 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was performed to investigate the effects of the chronic use of continuous, not eccentric, dosing of nitrates on cardiac events in patients with severe acute myocardial infarction." | 9.09 | Chronic use of continuous dosing of long-term nitrates does not prevent cardiac events in patients with severe acute myocardial infarction. ( Hayashi, T; Ikeda, A; Ishikawa, K; Kanamasa, K; Kimura, A; Takenaka, T, 2000) |
| "The aim of this study was to evaluate the hemodynamic effect of L-arginine infusion in patients with congestive heart failure." | 9.08 | Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. ( Blum, M; Bogomolny, N; Chernichowsky, T; Finkelstein, A; Iaina, A; Koifman, B; Laniado, S; Peer, G; Scherez, J; Wollman, Y, 1995) |
| "This study was designed to investigate the effect of angiotensin-converting enzyme (ACE) inhibitors with and without a sulfhydryl group on intracellular production of cGMP, forearm blood flow, and neurohormonal factors during continuous transdermal application of nitroglycerin in patients with chronic heart failure." | 9.08 | Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "To evaluate the mechanisms involved in nitrate tolerance, we randomized 23 patients with congestive heart failure resulting from coronary artery disease to an isosorbide dinitrate or a molsidomine infusion." | 9.07 | Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. ( Berkenboom, G; de Cannière, D; Staroukine, M; Unger, P; Vachiery, JL, 1994) |
| "Although nitrates produce marked decreases in ventricular filling pressures in patients with severe heart failure, their therapeutic value has long been believed to be limited because they were thought to exert minimal arterial dilating effects." | 9.05 | New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure. ( Packer, M, 1983) |
| "Hydralazine (H) and nitrates (Ns), when combined, reduced morbidity and mortality in some trials of chronic heart failure (CHF)." | 8.91 | Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. ( Clark, AL; Cleland, JG; Farag, M; Mabote, T; Nabhan, AF; Shoaib, A; Zhang, J, 2015) |
| "Nitrates are commonly used in the therapy of congestive heart failure (CHF)." | 8.79 | Nitrates in congestive heart failure. ( Dupuis, J, 1994) |
| "Organic nitrates have been used widely in the treatment of chronic congestive heart failure." | 8.79 | Nitrates in heart failure. ( Elkayam, U, 1994) |
| "Nitrates have been widely used for the treatment of patients with chronic congestive heart failure." | 8.79 | Nitrates in the treatment of congestive heart failure. ( Elkayam, U, 1996) |
| "For nitrates their efficacy in acute and chronic heart failure has to be differentiated." | 8.79 | [The role of nitrates in therapy of heart failure]. ( Strasser, RH, 1996) |
| "In this revision article, after referring the mechanisms of action of nitrates in the relief of heart failure symptoms, the author presents the results of the controlled studies which show the beneficial effect of the nitrates on heart failure symptoms and mortality." | 8.78 | [Nitrates in the treatment of congestive heart failure]. ( Bordalo e Sá, AL, 1993) |
| "The efficacy of nitrates versus that of angiotensin-converting enzyme (ACE) inhibitors in heart failure may be evaluated based on 3 treatment aims: hemodynamic improvement, symptom relief, and survival benefit." | 8.78 | Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure. ( Cohn, JN, 1993) |
| "In this revision article, after referring the mechanisms of action of nitrates in the relief of heart failure symptoms, the author presents the results of the controlled studies which show the beneficial effect of the nitrates on heart failure symptoms and mortality." | 8.78 | [The use of nitrates in the treatment of heart failure]. ( Bordalo e Sá, AL, 1993) |
| "Nitrates exert hemodynamic and possibly nonhemodynamic effects that result in reduced cardiac filling pressures, increased cardiac output, reduced pulmonary vascular pressures, and improvement in symptoms and exercise tolerance in patients with heart failure." | 8.78 | Mechanisms of action and efficacy of nitrates in heart failure. ( Cohn, JN, 1992) |
| " There are five randomized trials of oral nitrates after acute myocardial infarction." | 8.78 | Effects of nitrates on mortality in acute myocardial infarction and in heart failure. ( Held, P, 1992) |
| " In order to evaluate the relationship between the mode of action of nitrates at cellular level and their vasodilatory effectiveness, we studied the circulatory response of the forearm to isosorbide dinitrate and the influence of nitroglycerin on free calcium concentration in the platelets in 10 patients with chronic heart failure." | 8.78 | Relationship between the inhibition of receptor-induced increase in cytosolic free calcium concentration and the vasodilator effects of nitrates in patients with congestive heart failure. ( Baldenkov, GN; Mazaev, AV; Mukharliamov, NM; Negrescu, EV; Sazonova, LN; Tkachuk, VA, 1990) |
| "Organic nitrates were the first peripherally-active vasodilators to be used for the treatment of heart failure." | 8.78 | [Nitrates in the treatment of heart failure]. ( Dirschinger, J; Hall, D; Rudolph, W, 1990) |
| "An important role for nitrates in the treatment of patients with congestive heart failure has been demonstrated." | 8.77 | Nitrates in congestive heart failure. ( Charlap, S; Frishman, WH; Herman, BM, 1989) |
| "The literature available on the use of nitrates (glyceryl trinitrate, isosorbide dinitrate and isosorbide 5-mononitrate) as various formulations (oral, buccal, sublingual, transdermal and intravenous) in the treatment of acute and chronic congestive heart failure is reviewed." | 8.77 | Use of nitrates in acute and chronic congestive heart failure. ( Swedberg, K, 1987) |
| "Hydralazine and nitrate combination was the first treatment that showed improved survival of patients with heart failure with reduced left ventricular ejection fraction (HFREF) in the Vasodilator Heart Failure Trial (V-HeFT trial) in 1986." | 7.91 | Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction. ( Al-Mohammad, A, 2019) |
| "Nitrates may be beneficial in heart failure with preserved ejection fraction (HFpEF) by enhancing cGMP signaling and improving hemodynamics, but real-world data on potential efficacy are lacking." | 7.85 | Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. ( Benson, L; Dahlström, U; Lam, CS; Lim, SL; Lund, LH, 2017) |
| "Both inorganic nitrate and citrulline are known to alter the arginine-nitric oxide-nitrate system to increase the bioavailability of nitric oxide with potential benefits in the treatment of heart failure." | 7.83 | Oral nitrate and citrulline decrease blood pressure and increase vascular conductance in young adults: a potential therapy for heart failure. ( Alsop, P; Hauton, D, 2016) |
| "A survey of members of the Heart Failure Society of America revealed that despite their lack of approval by the United States Food and Drug Administration, nitrates are widely used in patients with chronic congestive heart failure (CHF)." | 7.72 | Survey of the use of organic nitrates for the treatment of chronic congestive heart failure in the United States. ( Akhter, MW; Bitar, F; Elkayam, U; Khan, S; Singh, H, 2004) |
| "To specifically assess the synthetic activity of the L-arginine-NO metabolic pathway, urinary excretion of [15N]nitrates and [15N]urea was determined after a primed continuous intravenous infusion of L-[15N]arginine (40 micromol/kg) in 16 patients with congestive heart failure and 9 age-matched normal control subjects at rest and during submaximal treadmill exercise." | 7.70 | Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. ( Katz, SD; Khan, T; Knecht, M; Mathew, L; Potharlanka, P; Whelan, J; Zeballos, GA, 1999) |
| "We examined the effects of chronic oral L-arginine treatment on endothelial and cardiovascular function in rats with heart failure induced by coronary artery ligation." | 7.70 | Effects of L-arginine on endothelial and cardiac function in rats with heart failure. ( Arnold, JM; Arnold, O; Feng, Q; Fortin, AJ; Lu, X, 1999) |
| "The use of nitrates in various sublingual, oral, topical and intravenous forms of treatment of patients with congestive heart failure (CHF) is based on their efficacy in dilating capacitance vessels and reducing elevated ventricular diastolic pressure on both the left and right sides of the heart." | 7.67 | Nitrates for congestive heart failure. ( Cohn, JN, 1985) |
| " Hemodynamic effects o high doses of oral isosorbide dinitrate in patients with chronic heart failure (N - 13)." | 7.66 | Hemodynamic effects of nitrates in chronic heart failure and myocardial infarction. ( Chatterjee, K, 1980) |
| "In patients with congestive heart failure, 1 hour after administration of 4 mg of molsidomine there were significant reductions in systolic and diastolic pulmonary artery pressures of 25% and 30%, respectively." | 6.66 | Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure. ( Dirschinger, J; Rudolph, W, 1985) |
| "Nitrates have been used as vasodilators in AHFS for many years and have been shown to improve some aspects of AHFS in some small studies." | 6.49 | Nitrates for acute heart failure syndromes. ( Brooks, SC; Diercks, DB; Fermann, GJ; Kidney, R; McCabe, A; Pospisil, C; Salter, N; Seupaul, RA; Wakai, A, 2013) |
| " The clinical implications of these hemodynamic results are discussed with emphasis on the short- and long-term use of nitrates in congestive heart failure." | 6.39 | [Nitrates in heart failure: the hemodynamic effects and clinical implications]. ( Faggiano, P; Ghizzoni, G; Rusconi, C, 1994) |
| "Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate (GMP) pathway." | 5.62 | Vericiguat, organic nitrates, and heart failure in African Americans. ( Guglin, M; Ilonze, OJ, 2021) |
| "enalapril alone to enhance vascular effects, increase LV contractility and prevent unfavorable remodeling and are consistent with vascular delivery of exogenous NO." | 5.32 | A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. ( Condorelli, G; Del Soldato, P; Dieterle, T; Gu, Y; Iwanaga, Y; Ongini, E; Peterson, KL; Presotto, C; Ross, J, 2004) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 5.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Nitroglycerin has long been a mainstay of the treatment of ischemic cardiac pain." | 5.27 | The role of transdermal nitroglycerin in the treatment of coronary heart disease. ( Taylor, SH, 1986) |
| " Although the safety profile of nifedipine has been generally regarded as favorable, a few reports of clinically significant adverse effects in specific patient groups have appeared in the literature." | 5.26 | Nifedipine therapy in angina pectoris: evaluation of safety and side effects. ( Terry, RW, 1982) |
| "Therefore, in 7 patients with congestive heart failure due to congestive cardiomyopathy, hemodynamic measurements were made using a Swan Ganz thermodilution catheter and cardiac output computer." | 5.26 | Enhancement of phentolamine by nitrates in patients with congestive heart failure. ( Gould, L; Reddy, CV; Singh, BK; Zen, B, 1981) |
| " The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline." | 5.14 | Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). ( Charbonnel, B; Erdmann, E; Spanheimer, R, 2010) |
| "Chronic heart failure is associated with increased levels of hypoxanthine and decreased levels of nitrite." | 5.11 | Home-based exercise training modulates pro-oxidant substrates in patients with chronic heart failure. ( Böger, R; Clark, AL; Coats, AJ; Niebauer, J; Webb-Peploe, KM, 2005) |
| "This study was performed to investigate the effects of the chronic use of continuous, not eccentric, dosing of nitrates on cardiac events in patients with severe acute myocardial infarction." | 5.09 | Chronic use of continuous dosing of long-term nitrates does not prevent cardiac events in patients with severe acute myocardial infarction. ( Hayashi, T; Ikeda, A; Ishikawa, K; Kanamasa, K; Kimura, A; Takenaka, T, 2000) |
| "The aim of this study was to evaluate the hemodynamic effect of L-arginine infusion in patients with congestive heart failure." | 5.08 | Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. ( Blum, M; Bogomolny, N; Chernichowsky, T; Finkelstein, A; Iaina, A; Koifman, B; Laniado, S; Peer, G; Scherez, J; Wollman, Y, 1995) |
| "Nitrates dilate coronary arteries, ameliorate myocardial ischemia, minimize left ventricular remodeling, and reduce mortality in patients with acute myocardial infarction." | 5.08 | Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. ( Arai, M; Aso, N; Hama, J; Ishikawa, K; Kamata, N; Kanamasa, K; Katori, Y; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yabushita, H; Yamamoto, K; Yamamoto, T, 1996) |
| "This study was designed to investigate the effect of angiotensin-converting enzyme (ACE) inhibitors with and without a sulfhydryl group on intracellular production of cGMP, forearm blood flow, and neurohormonal factors during continuous transdermal application of nitroglycerin in patients with chronic heart failure." | 5.08 | Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "To evaluate the mechanisms involved in nitrate tolerance, we randomized 23 patients with congestive heart failure resulting from coronary artery disease to an isosorbide dinitrate or a molsidomine infusion." | 5.07 | Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. ( Berkenboom, G; de Cannière, D; Staroukine, M; Unger, P; Vachiery, JL, 1994) |
| "Angiotensin-converting enzyme (ACE) inhibition slowed the progression of congestive heart failure (CHF) in 170 patients who were randomly assigned to either captopril or placebo in the Munich Mild Heart Failure Trial." | 5.07 | Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition. ( Doering, W; Fischer, M; Kleber, FX; Niemöller, L, 1991) |
| "The prostaglandin-thromboxane system, platelet hemostasis and central hemodynamics were evaluated in 51 patients with heart failure-complicated acute myocardial infarction during aspirin, roxicam and basic (nitrates + cardiac glycosides + diuretics) therapies." | 5.07 | [Pharmacological correction by roxicam of the prostacyclin-thromboxane system in acute myocardial infarction complicated by heart failure]. ( Khosseĭn Shakhavat, AF; Shelest, AN; Shushliapin, OI, 1991) |
| "Although nitrates produce marked decreases in ventricular filling pressures in patients with severe heart failure, their therapeutic value has long been believed to be limited because they were thought to exert minimal arterial dilating effects." | 5.05 | New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure. ( Packer, M, 1983) |
| "Nitrates and nitrate-containing compounds are vasodilators used for the treatment of angina and heart failure." | 4.98 | A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. ( Goggin, P; Goldstein, I; Hackett, G; Kirby, MG; Kloner, RA; Osterloh, I; Parker, JD; Sadovsky, R, 2018) |
| "Hydralazine (H) and nitrates (Ns), when combined, reduced morbidity and mortality in some trials of chronic heart failure (CHF)." | 4.91 | Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. ( Clark, AL; Cleland, JG; Farag, M; Mabote, T; Nabhan, AF; Shoaib, A; Zhang, J, 2015) |
| " For symptomatic treatment and prevention of angina pectoris, beta-blockers, calcium channel blockers, nitrates, I((f)) (funny channel) blockers and ranolazine are effective." | 4.88 | [Conservative therapy of patients with stable coronary heart disease]. ( Custodis, F; Laufs, U, 2012) |
| "Organic nitrates still are one of the most important drug classes used in the treatment of an acute coronary syndrome and stable coronary artery disease as well as acute and chronic congestive heart failure." | 4.84 | [Recent findings on nitrates: their action, bioactivation and development of tolerance]. ( Münzel, T, 2008) |
| "Glyceryl trinitrate, isosorbide dinitrate, and isosorbide-5-mononitrate are organic nitrate esters commonly used in the treatment of angina pectoris, myocardial infarction, and congestive heart failure." | 4.79 | Mechanisms of action of nitrates. ( Ahlner, J; Torfgård, KE, 1994) |
| "There is now little dispute that clinical tolerance of organic nitrates occurs, particularly when these drugs are used by themselves to treat patients with stable angina pectoris and congestive heart failure." | 4.79 | Mechanisms of nitrate tolerance. ( Bauer, JA; Fung, HL, 1994) |
| "Nitrates are commonly used in the therapy of congestive heart failure (CHF)." | 4.79 | Nitrates in congestive heart failure. ( Dupuis, J, 1994) |
| "Organic nitrates have been used widely in the treatment of chronic congestive heart failure." | 4.79 | Nitrates in heart failure. ( Elkayam, U, 1994) |
| "Nitrates have been widely used for the treatment of patients with chronic congestive heart failure." | 4.79 | Nitrates in the treatment of congestive heart failure. ( Elkayam, U, 1996) |
| "For nitrates their efficacy in acute and chronic heart failure has to be differentiated." | 4.79 | [The role of nitrates in therapy of heart failure]. ( Strasser, RH, 1996) |
| "In this revision article, after referring the mechanisms of action of nitrates in the relief of heart failure symptoms, the author presents the results of the controlled studies which show the beneficial effect of the nitrates on heart failure symptoms and mortality." | 4.78 | [Nitrates in the treatment of congestive heart failure]. ( Bordalo e Sá, AL, 1993) |
| "The efficacy of nitrates versus that of angiotensin-converting enzyme (ACE) inhibitors in heart failure may be evaluated based on 3 treatment aims: hemodynamic improvement, symptom relief, and survival benefit." | 4.78 | Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure. ( Cohn, JN, 1993) |
| "In this revision article, after referring the mechanisms of action of nitrates in the relief of heart failure symptoms, the author presents the results of the controlled studies which show the beneficial effect of the nitrates on heart failure symptoms and mortality." | 4.78 | [The use of nitrates in the treatment of heart failure]. ( Bordalo e Sá, AL, 1993) |
| "Nitrates exert hemodynamic and possibly nonhemodynamic effects that result in reduced cardiac filling pressures, increased cardiac output, reduced pulmonary vascular pressures, and improvement in symptoms and exercise tolerance in patients with heart failure." | 4.78 | Mechanisms of action and efficacy of nitrates in heart failure. ( Cohn, JN, 1992) |
| "Organic nitrates are commonly used in the treatment of chronic congestive heart failure (CHF)." | 4.78 | Nitrate resistance and tolerance: potential limitations in the treatment of congestive heart failure. ( Elkayam, U; Mehra, A; Ostrzega, E; Shotan, A, 1992) |
| " There are five randomized trials of oral nitrates after acute myocardial infarction." | 4.78 | Effects of nitrates on mortality in acute myocardial infarction and in heart failure. ( Held, P, 1992) |
| " In order to evaluate the relationship between the mode of action of nitrates at cellular level and their vasodilatory effectiveness, we studied the circulatory response of the forearm to isosorbide dinitrate and the influence of nitroglycerin on free calcium concentration in the platelets in 10 patients with chronic heart failure." | 4.78 | Relationship between the inhibition of receptor-induced increase in cytosolic free calcium concentration and the vasodilator effects of nitrates in patients with congestive heart failure. ( Baldenkov, GN; Mazaev, AV; Mukharliamov, NM; Negrescu, EV; Sazonova, LN; Tkachuk, VA, 1990) |
| "Organic nitrates were the first peripherally-active vasodilators to be used for the treatment of heart failure." | 4.78 | [Nitrates in the treatment of heart failure]. ( Dirschinger, J; Hall, D; Rudolph, W, 1990) |
| " The dilatation of veins induced by nitrates explains also their effectiveness in patients suffering from heart failure with high left ventricular pressure." | 4.78 | [Current status of pharmacology and therapeutic use of nitro derivatives]. ( Costa, R; Marino, A, 1990) |
| "An important role for nitrates in the treatment of patients with congestive heart failure has been demonstrated." | 4.77 | Nitrates in congestive heart failure. ( Charlap, S; Frishman, WH; Herman, BM, 1989) |
| "Tolerance develops during the prolonged use of organic nitrates in patients with chronic heart failure in a fashion similar to its development in patients with angina pectoris, the magnitude of tolerance development being directly proportional to the frequency of dosing." | 4.77 | The clinical significance of nitrate tolerance in patients with chronic heart failure. ( Packer, M, 1989) |
| "The role of transdermal nitroglycerin (TNTG) in the treatment of ischemic heart disease and congestive heart failure (CHF) is reviewed, with an emphasis on controversies concerning efficacy, hemodynamics, and dosing." | 4.77 | Controversies in the use of transdermal nitroglycerin systems. ( Klamerus, KJ; Zeller, FP, 1987) |
| "Nitroglycerin and the long-acting nitrates are beneficial in stable and unstable angina pectoris and acute myocardial infarction and as adjunctive therapy in congestive heart failure." | 4.77 | A reappraisal of nitrate therapy. ( Abrams, J, 1988) |
| "The literature available on the use of nitrates (glyceryl trinitrate, isosorbide dinitrate and isosorbide 5-mononitrate) as various formulations (oral, buccal, sublingual, transdermal and intravenous) in the treatment of acute and chronic congestive heart failure is reviewed." | 4.77 | Use of nitrates in acute and chronic congestive heart failure. ( Swedberg, K, 1987) |
| "Nitrates are vasodilators of venous and arterial smooth muscle commonly prescribed both for angina and congestive heart failure." | 4.77 | Nitrate therapy in angina and congestive heart failure. ( Cohn, PF; Vlay, SC, 1985) |
| "Nitroglycerin has been the mainstay of the medical management of angina pectoris for over 100 years." | 4.76 | The transdermal administration of nitrates: an overview. ( Demma, FJ; Wilson, RR, 1983) |
| " Nitrates are routinely used for the treatment of stable and unstable angina and also play a role in therapy for complications of myocardial infarction." | 4.76 | Nitrate delivery systems in perspective. A decade of progress. ( Abrams, J, 1984) |
| "The expanding applications of nitroglycerin and nitrate esters--in congestive heart failure, in the reduction of infarct size in myocardial infarction and in the long-term prophylaxis of angina--have enhanced the clinical importance of these drugs." | 4.75 | Nitroglycerin and nitrate esters. ( Francis, GS; Warren, SE, 1978) |
| "Hydralazine and nitrate combination was the first treatment that showed improved survival of patients with heart failure with reduced left ventricular ejection fraction (HFREF) in the Vasodilator Heart Failure Trial (V-HeFT trial) in 1986." | 3.91 | Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction. ( Al-Mohammad, A, 2019) |
| "Nitrates may be beneficial in heart failure with preserved ejection fraction (HFpEF) by enhancing cGMP signaling and improving hemodynamics, but real-world data on potential efficacy are lacking." | 3.85 | Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. ( Benson, L; Dahlström, U; Lam, CS; Lim, SL; Lund, LH, 2017) |
| "There is limited evidence that the use of nitrates in acute decompensated heart failure early after presentation to a hospital can improve clinical outcomes." | 3.83 | Impact of Nitrate Use on Survival in Acute Heart Failure: A Propensity-Matched Analysis. ( Austin, PC; Ho, EC; Lee, DS; Parker, JD; Tu, JV; Wang, X, 2016) |
| "There is a lack of knowledge on the effects of nitrates alone in heart failure (HF)." | 3.83 | Impact of Chronic Nitrate Therapy in Patients With Ischemic Heart Failure. ( Bettencourt, P; Moreira-Silva, S; Nogueira-Silva, L; Pimenta, J; Urbano, J, 2016) |
| "Both inorganic nitrate and citrulline are known to alter the arginine-nitric oxide-nitrate system to increase the bioavailability of nitric oxide with potential benefits in the treatment of heart failure." | 3.83 | Oral nitrate and citrulline decrease blood pressure and increase vascular conductance in young adults: a potential therapy for heart failure. ( Alsop, P; Hauton, D, 2016) |
| "There is little evidence on the prognostic influence of intravenous nitrates in patients with acute heart failure." | 3.81 | Influence of Intravenous Nitrate Treatment on Early Mortality Among Patients With Acute Heart Failure. NITRO-EAHFE Study. ( Herrero-Puente, P; Jacob, J; Llorens, P; Lucas-Imbernón, FJ; Martín-Sánchez, FJ; Martínez-Camblor, P; Martínez-Zapico, A; Miró, Ò; Vázquez-Álvarez, J, 2015) |
| "Combination therapy with hydralazine and nitrates can improve outcomes in patients with heart failure and low ejection fraction." | 3.79 | Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. ( Butler, J; Fonarow, GC; Georgiopoulou, VV; Gheorghiade, M; Gupta, D; Kalogeropoulos, AP; Konstam, MA; Marti, CN; Yancy, CW, 2013) |
| "A total of 128 consecutive acute heart failure patients were either treated with standard therapy or high-dose sublingual and transdermal nitrates on top of standard of care treatment." | 3.76 | Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study. ( Breidthardt, T; Christ, M; Egli, P; Gayat, E; Hartwiger, S; Mebazaa, A; Mueller, C; Noveanu, M; Potocki, M; Reichlin, T; Socrates, T, 2010) |
| "To examine the role of endothelin ETA and ETB receptors in congestive heart failure due to cardiomyopathy, the effect of chronic treatment with selective ETA- and ETB-receptor antagonists (atrasentan and A-192621, respectively), alone and in combination, was assessed on functional and biochemical parameters of 52-week-old Bio 14." | 3.74 | Nonselective ETA/ETB-receptor blockade increases systemic blood pressure of Bio 14.6 cardiomyopathic hamsters. ( Bkaily, G; Carrier, E; D'Orleans-Juste, P; Fecteau, MH; Honoré, JC; Tirapelli, CR, 2008) |
| "A survey of members of the Heart Failure Society of America revealed that despite their lack of approval by the United States Food and Drug Administration, nitrates are widely used in patients with chronic congestive heart failure (CHF)." | 3.72 | Survey of the use of organic nitrates for the treatment of chronic congestive heart failure in the United States. ( Akhter, MW; Bitar, F; Elkayam, U; Khan, S; Singh, H, 2004) |
| "To specifically assess the synthetic activity of the L-arginine-NO metabolic pathway, urinary excretion of [15N]nitrates and [15N]urea was determined after a primed continuous intravenous infusion of L-[15N]arginine (40 micromol/kg) in 16 patients with congestive heart failure and 9 age-matched normal control subjects at rest and during submaximal treadmill exercise." | 3.70 | Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. ( Katz, SD; Khan, T; Knecht, M; Mathew, L; Potharlanka, P; Whelan, J; Zeballos, GA, 1999) |
| " In rats with heart failure, the concentration-response curve of the endothelium-dependent vasodilator acetylcholine (after preconstriction with phenylephrine) was significantly shifted to the right, and the maximum relaxation was attenuated." | 3.70 | Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. ( Bauersachs, J; Bouloumié, A; Busse, R; Ertl, G; Fraccarollo, D; Hu, K, 1999) |
| "We examined the effects of chronic oral L-arginine treatment on endothelial and cardiovascular function in rats with heart failure induced by coronary artery ligation." | 3.70 | Effects of L-arginine on endothelial and cardiac function in rats with heart failure. ( Arnold, JM; Arnold, O; Feng, Q; Fortin, AJ; Lu, X, 1999) |
| "Nitroglycerin, when administered to patients with heart failure, causes a marked reduction in left ventricular filling pressure but often an increase in stroke volume and stroke work; based on the Frank-Starling principle, such a reduction in "preload" would be expected to result in a decrease in left ventricular end-diastolic volume and, therefore, a decline in stroke volume." | 3.67 | Mechanism of action of nitrates. Role of changes in venous capacitance and in the left ventricular diastolic pressure-volume relation. ( Belenkie, I; Kingma, I; Manyari, D; Smiseth, OA; Smith, ER; Tyberg, JV, 1984) |
| "The use of nitrates in various sublingual, oral, topical and intravenous forms of treatment of patients with congestive heart failure (CHF) is based on their efficacy in dilating capacitance vessels and reducing elevated ventricular diastolic pressure on both the left and right sides of the heart." | 3.67 | Nitrates for congestive heart failure. ( Cohn, JN, 1985) |
| " Hemodynamic effects o high doses of oral isosorbide dinitrate in patients with chronic heart failure (N - 13)." | 3.66 | Hemodynamic effects of nitrates in chronic heart failure and myocardial infarction. ( Chatterjee, K, 1980) |
| "To assess the clinical efficacy of chronic vasodilator therapy for refractory congestive heart failure, the long-term follow-up (mean 13 months, range 3-30 months) was evaluated in 56 patients treated with hydralazine, usually in combination with nitrates." | 3.66 | Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. ( Chatterjee, K; Haughom, F; Massie, B; O'Young, J; Ostland, J; Parmley, W; Ports, T, 1981) |
| "The results of this study with 102 patients, suffering from cardiac insufficiency and coronary heart disease are that a fixed combination of digoxin with nitrate-compositions is not convenient." | 3.66 | [Do fixed combinations of digoxin and nitrates have a therapeutic advantage?]. ( Mattern, HJ, 1981) |
| "Ten patients with severe congestive heart failure after acute myocardial infarction were treated with 40 mg isosorbiddinitrate-retard every 4 hours and additional sublingual nitroglycerine." | 3.66 | [Peroral nitrate therapy in severe cardiac insufficiency following acute myocardial infarct]. ( Baitsch, G; Bertel, O; Burkart, F; Elsässer, S; Ritz, R, 1978) |
| " New drugs for the treatment of severe congestive heart failure include dopamine, which has a selective nonadrenergic dilator effect on the renal vascular bed, and dobutamine, which has potent inotropic effects, lowers the left ventricular filling pressure and does not increase the heart rate or the systemic vascular resistance." | 3.66 | Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. ( Armstrong, PW, 1979) |
| "Furosemide was administered intravenously to 11 patients with cardiac failure after acute myocardial infarction." | 3.66 | [Hemodynamic consequences of the furosemide treatment of cardiac insufficiency in recent myocardial infarct]. ( Baitsch, G; Bertel, O; Burkart, F; Ritz, R; Steiner, A; Vettiger, K, 1979) |
| "This study sought to determine whether a relatively low single dose or a week-long dosage of dietary inorganic nitrate could improve exercise tolerance in patients with heart failure with preserved ejection fraction (HFpEF)." | 2.82 | One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction. ( Basu, S; Brubaker, P; Eggebeen, J; Haykowsky, M; Kim-Shapiro, DB; Kitzman, DW; Morgan, TM; Rejeski, J, 2016) |
| "Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge." | 2.82 | Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions? ( Bowlin, B; Finch, C; Hartmann, J; Reedus, J; Richardson, A; Sands, CW; Self, T; Tolley, E, 2016) |
| "In this pilot study, acute dietary NO3 (-) intake was well tolerated and enhanced NO bioavailability and muscle power in patients with systolic heart failure." | 2.80 | Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial. ( Coggan, AR; Farmer, M; Kadkhodayan, A; Leibowitz, JL; Mahmood, K; Park, S; Peterson, LR; Ramamurthy, S; Spearie, CA; Thomas, DP; Waller, S, 2015) |
| "Nitrates were given to 947/1048 (90." | 2.75 | Diuretic, opiate and nitrate use in severe acidotic acute cardiogenic pulmonary oedema: analysis from the 3CPO trial. ( Goodacre, S; Gray, A; Seah, M; Tilley, S, 2010) |
| " Among such questions are: When in the natural history of congestive heart failure should vasodilator therapy be commenced? How effective is long-term administration of vasodilating drugs? May vasodilator therapy decrease mortality in congestive heart failure? What about the efficacy of new vasodilating drugs compared to more traditional ones? In the review of vasodilating drugs besides ACE inhibitors, these questions will be addressed." | 2.66 | Aspects on "traditional" vasodilators in the treatment of chronic heart failure. ( Conradson, TB; Rydén, L, 1986) |
| "In patients with congestive heart failure, 1 hour after administration of 4 mg of molsidomine there were significant reductions in systolic and diastolic pulmonary artery pressures of 25% and 30%, respectively." | 2.66 | Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure. ( Dirschinger, J; Rudolph, W, 1985) |
| " Potential mechanisms include decreased oxidative stress, homocysteine and inflammation but higher antioxidant defence and NO bioavailability and gut microbiome modulation." | 2.61 | Dietary patterns and components to prevent and treat heart failure: a comprehensive review of human studies. ( Kerley, CP, 2019) |
| " Multiple lines of evidence point to impaired nitric oxide (NO)-cGMP bioavailability as playing a central role in each of these abnormalities." | 2.55 | INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. ( Anstrom, K; Borlaug, BA; Braunwald, E; Davila-Roman, VG; Hernandez, A; LeWinter, M; Lewis, GD; Reddy, YNV; Redfield, MM; Semigran, M; Shah, SJ, 2017) |
| "Hypertension is the leading risk factor for cardiovascular diseases." | 2.55 | Guide of Hypertensive Crisis Pharmacotherapy. ( Blanco-Garcia, C; Mendez, M; Mukherjee, D; Wani-Parekh, P, 2017) |
| " A decrease in the production and bioavailability of NO is a hallmark of many major chronic diseases including hypertension, ischaemia-reperfusion injury, atherosclerosis and diabetes." | 2.53 | Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases. ( Lundberg, JO; Omar, SA; Webb, AJ; Weitzberg, E, 2016) |
| "Acute heart failure is a major cause of emergency hospital admission, with significant impact on health resources and patient outcomes." | 2.50 | The role of intravenous vasodilators in acute heart failure management. ( McDonagh, T; Piper, S, 2014) |
| "Nitrates have been used as vasodilators in AHFS for many years and have been shown to improve some aspects of AHFS in some small studies." | 2.49 | Nitrates for acute heart failure syndromes. ( Brooks, SC; Diercks, DB; Fermann, GJ; Kidney, R; McCabe, A; Pospisil, C; Salter, N; Seupaul, RA; Wakai, A, 2013) |
| "Nitrates have been commonly used in the therapy of cardiovascular disease for more than 150 years." | 2.47 | [Nitrates in cardiology: current role and areas of uncertainty]. ( Appignani, M; Bellisarii, FI; De Caterina, R; Muscente, F; Radico, F, 2011) |
| "Ivabradine is a new selective HR-lowering agent that selectively inhibits the pacemaker current I (f) in the sinus atrial node." | 2.45 | Ivabradine: beyond heart rate control. ( D'Orazio, N; Riccioni, G; Vitulano, N, 2009) |
| "This paper concerns the medical treatment of heart failure according to the recommendations of the European Society of Cardiology." | 2.44 | [Medical treatment of chronic heart failure]. ( Schüpfer, CA, 2007) |
| "Endothelial dysfunction, a critical component in the progression of heart failure, may result from increased oxidative stress, secondary to activation of the adrenergic and the renin-angiotensin systems and to the production of inflammatory cytokines, which in turn contribute to reduced bioavailability of nitric oxide (NO)." | 2.44 | Redox state, oxidative stress and endothelial dysfunction in heart failure: the puzzle of nitrate-thiol interaction. ( De Maria, R; Parodi, O; Roubina, E, 2007) |
| "It is now abundantly clear that congestive heart failure caused by a predominant abnormality in diastolic function (i." | 2.42 | Diastolic heart failure. Diagnosis, prognosis, treatment. ( Zile, MR, 2003) |
| "Acute heart failure is a common cause of referral and admission to hospital." | 2.41 | Acute heart failure: a practical guide to management. ( McMurray, JJ; Murdoch, DR, 2000) |
| " In these patients, beneficial antianginal and antiischemic effects of nitrates for 10-14 hours during the daytime can be maintained by using formulations and dosing regimens that avoid or minimize the development of tolerance (standard formulation of isosorbide-5-mononitrate, 20 mg in the morning and 7 hours later; slow-release formulation of isosorbide-5-mononitrate, 120-240 mg once a day; or nitroglycerin patch delivering 0." | 2.40 | Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. ( Thadani, U, 1997) |
| " Chronic use of other inotropic drugs for congestive left heart failure is not recommended." | 2.39 | [Chronic left heart ventricle failure and inotropic stimulation]. ( Dickstein, K; Gundersen, T; Hole, T; Kjekshus, J; Myhre, ES; Rønnevik, P; Smith, P; Westheim, A, 1995) |
| " The clinical implications of these hemodynamic results are discussed with emphasis on the short- and long-term use of nitrates in congestive heart failure." | 2.39 | [Nitrates in heart failure: the hemodynamic effects and clinical implications]. ( Faggiano, P; Ghizzoni, G; Rusconi, C, 1994) |
| "Heart failure is at the same time a muscular and a neurohormonal disease." | 2.39 | [Cardiac insufficiency: therapeutic aspects in the elderly person]. ( Perrenoud, JJ, 1996) |
| "Although the etiology of congestive heart failure is complex, a disturbance of myocardial function due to ischemic heart disease or various forms of cardiomyopathy is by far the leading causative factor." | 2.37 | Congestive heart failure--pathophysiology and medical treatment. ( Remme, WJ, 1986) |
| "Careful differential diagnosis of congestive heart failure is a critical pre-condition to starting any therapy for heart failure, particularly in the elderly patient." | 2.37 | Updated use of digitalis and nitrates in the elderly. ( Goldsmith, SR; Marx, S, 1988) |
| " New nitrate delivery systems have recently become available which provide considerable dosing flexibility, further increasing the interest in this group of compounds." | 2.37 | Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration. ( Abrams, J, 1987) |
| " Finally, appropriate dosing strategies are suggested that should eliminate the potential problem of nitrate tolerance." | 2.37 | Nitrates. ( Abrams, J, 1988) |
| "Reduced mortality rates in congestive heart failure with vasodilator therapy has not been demonstrated, and prediction of clinical response to therapy is difficult." | 2.37 | Vasodilator therapy. ( Sutton, FJ, 1986) |
| " It is appropriate that the patient's dosage of nitrates be administered with a formulation most likely to be both clinically effective and well tolerated." | 2.37 | Pharmacology of nitroglycerin and long-acting nitrates. ( Abrams, J, 1985) |
| " However, there are both clinical data and theoretic reasons to anticipate that some degree of tolerance may develop during the long-term use of most agents." | 2.36 | Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. ( Alexander, RW; Braunwald, E; Colucci, WS; Williams, GH, 1981) |
| "Diabetes complications included congestive heart failure, coronary heart disease, angina, stroke, myocardial infarction, diabetic retinopathy, and nephropathy." | 1.91 | Association of Urinary Nitrate With Diabetes Complication and Disease-Specific Mortality Among Adults With Hyperglycemia. ( Han, T; Jiang, W; Liu, S; Ma, L; Sun, C; Sun, X; Wei, W; Wu, H; Yang, R; Zhang, J, 2023) |
| "Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate (GMP) pathway." | 1.62 | Vericiguat, organic nitrates, and heart failure in African Americans. ( Guglin, M; Ilonze, OJ, 2021) |
| "Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently co-exist, and each is a major public health issue." | 1.43 | Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. ( Baviera, M; Bortolotti, A; Cortesi, L; Dal Bo, GA; Fortino, I; Latini, R; Merlino, L; Roncaglioni, MC; Staszewsky, L; Tettamanti, M, 2016) |
| " About 30% of patients received the target dosage of these drugs, but a documented reason for not achieving the target dosage was reported in almost two-thirds of them." | 1.39 | Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. ( Amir, O; Anker, SD; Chioncel, O; Dahlström, U; Drozdz, J; Erglis, A; Fazlibegovic, E; Filippatos, G; Fonseca, C; Fruhwald, F; Gatzov, P; Goncalvesova, E; Hassanein, M; Hradec, J; Kavoliuniene, A; Lainscak, M; Leiro, MC; Logeart, D; Maggioni, AP; Merkely, B; Metra, M; Persson, H; Ponikowski, P; Seferovic, P; Tavazzi, L; Temizhan, A; Tousoulis, D; Zannad, F, 2013) |
| "Nitrates were given most often in pulmonary oedema and hypertensive AHF." | 1.39 | Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies. ( Harjola, VP; Lassus, J; Nieminen, MS; Siirilä-Waris, K; Tarvasmäki, T; Tolonen, J, 2013) |
| "The Maastricht Registry of Congestive Heart Failure consists of a cohort of all patients who were admitted to the University Hospital Maastricht because of CHF for the first time between 1998 and 2000." | 1.33 | Statins associated with reduced mortality in patients admitted for congestive heart failure. ( Crijns, HJ; Folkeringa, RJ; Nieman, FH; Pinto, YM; Tieleman, RG; Van Kraaij, DJ, 2006) |
| "To evaluate the impact of new medical treatments for heart failure between 1990 and 1998." | 1.32 | Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. ( Bouvy, ML; Heerdink, ER; Hoes, AW; Leufkens, HG, 2003) |
| "enalapril alone to enhance vascular effects, increase LV contractility and prevent unfavorable remodeling and are consistent with vascular delivery of exogenous NO." | 1.32 | A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. ( Condorelli, G; Del Soldato, P; Dieterle, T; Gu, Y; Iwanaga, Y; Ongini, E; Peterson, KL; Presotto, C; Ross, J, 2004) |
| "Heart failure is associated with an increase in plasma nitrate and nitrite (NOx)." | 1.31 | Plasma nitrate accumulation during the development of pacing-induced dilated cardiac myopathy in conscious dogs is due to renal impairment. ( Hintze, TH; Laycock, S; Ochoa, M; Osorio, JC; Vogel, T; Xu, X, 2001) |
| "Heart failure was induced in rats by myocardial infarction (left coronary artery ligation) and confirmed by histological analysis at 8 weeks postinfarct (1." | 1.31 | Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. ( Bauer, JA; Coyle, CM; Mihm, MJ; Schanbacher, BL; Weinstein, DM, 2001) |
| " Long-term administration (2 mo) of the selective NOS II inhibitor S-methylisothiourea (SMT) to rats with MI significantly improved cardiac function." | 1.31 | Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. ( Fahas, L; Giaid, A; Hu, F; Saito, T; Shennib, H; Tayara, L, 2002) |
| "Heart failure is associated with an increase in plasma nitrate levels, and yet most experimental evidence demonstrates a reduction in endothelial nitric oxide production during heart failure." | 1.30 | Mechanisms of nitrate accumulation in plasma during pacing-induced heart failure in conscious dogs. ( Bernstein, RD; Forfia, P; Hintze, TH; Ochoa, F; Ochoa, M; Tuzman, J; Vogel, T; Zhang, X; Zhao, G, 1997) |
| "Beta blockers are also effective in the treatment of angina pectoris, and despite their side effects, are particularly useful in effort angina." | 1.27 | Rational medical therapy for stable angina pectoris. ( Abrams, J; Hoekenga, D, 1984) |
| "Only in rare cases with cardiac failure or with rapid atrial fibrillation glycosides will be necessary." | 1.27 | [Therapy of angina pectoris]. ( Sterz, H, 1984) |
| "Drug therapy of angina pectoris and arrhythmias after myocardial infarction is basically the same as in patients without a history of infarction." | 1.27 | [Diagnosis and drug therapy in the postinfarct phase]. ( Kronik, G, 1984) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 1.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Nitroglycerin has long been a mainstay of the treatment of ischemic cardiac pain." | 1.27 | The role of transdermal nitroglycerin in the treatment of coronary heart disease. ( Taylor, SH, 1986) |
| " Although the safety profile of nifedipine has been generally regarded as favorable, a few reports of clinically significant adverse effects in specific patient groups have appeared in the literature." | 1.26 | Nifedipine therapy in angina pectoris: evaluation of safety and side effects. ( Terry, RW, 1982) |
| " Comparisons, however, are difficult owing to different methods and dosage regimens and to the isolated character of too many case-reports." | 1.26 | [Long-acting nitrate compounds (author's transl)]. ( Lhoste, F, 1980) |
| "Vasodilator treatment of congestive heart failure has provided an important new role for long-acting nitrates." | 1.26 | Nitrate tolerance and dependence. A critical assessment. ( Abrams, J, 1980) |
| "Therefore, in 7 patients with congestive heart failure due to congestive cardiomyopathy, hemodynamic measurements were made using a Swan Ganz thermodilution catheter and cardiac output computer." | 1.26 | Enhancement of phentolamine by nitrates in patients with congestive heart failure. ( Gould, L; Reddy, CV; Singh, BK; Zen, B, 1981) |
| "Nitrates principally cause vasodilation, nitroprusside, phentolamine and prazosin produce balanced arterial and venous dilation, whereas hydralazine predominantly causes arteriolar dilation." | 1.26 | [Differential therapy of heart insufficiency]. ( Gilfrich, HJ, 1982) |
| " Lesser problems include the construction of effective dosage schedules, deleterious effects after sudden withdrawal, development of tolerance, and side effects." | 1.26 | The longer term efficacy of vasodilators in heart failure. ( Hernandez, J; Owens, CW, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 116 (34.42) | 18.7374 |
| 1990's | 73 (21.66) | 18.2507 |
| 2000's | 51 (15.13) | 29.6817 |
| 2010's | 75 (22.26) | 24.3611 |
| 2020's | 22 (6.53) | 2.80 |
| Authors | Studies |
|---|---|
| Sandhu, AT | 1 |
| Kohsaka, S | 1 |
| Turakhia, MP | 1 |
| Lewis, EF | 1 |
| Heidenreich, PA | 1 |
| Namba, T | 1 |
| Masaki, N | 1 |
| Hitomi, Y | 1 |
| Ishinoda, Y | 1 |
| Iwashita, M | 1 |
| Yumita, Y | 1 |
| Kagami, K | 1 |
| Yasuda, R | 1 |
| Ikegami, Y | 1 |
| Toya, T | 1 |
| Nagatomo, Y | 1 |
| Takase, B | 1 |
| Soejima, K | 1 |
| Adachi, T | 1 |
| Huang, L | 3 |
| Pang, L | 1 |
| Gu, Q | 1 |
| Yang, T | 1 |
| Li, W | 4 |
| Quan, R | 1 |
| Su, W | 1 |
| Wu, W | 2 |
| Tang, F | 1 |
| Zhu, X | 2 |
| Shen, J | 1 |
| Sun, J | 3 |
| Shan, G | 1 |
| Xiong, C | 1 |
| Huang, S | 1 |
| He, J | 1 |
| Warner, AL | 1 |
| Lu, L | 1 |
| Ghaznavi, Z | 1 |
| Jackevicius, CA | 1 |
| Goncalvesova, E | 2 |
| Dankova, M | 1 |
| Lesny, P | 1 |
| Luknar, M | 1 |
| Jiang, W | 1 |
| Zhang, J | 6 |
| Yang, R | 2 |
| Sun, X | 3 |
| Wu, H | 1 |
| Liu, S | 3 |
| Sun, C | 1 |
| Ma, L | 2 |
| Han, T | 1 |
| Wei, W | 1 |
| Jouini, S | 1 |
| Manai, H | 1 |
| Slimani, O | 1 |
| Hedhli, H | 1 |
| Hebaieb, F | 1 |
| Mezghanni, M | 1 |
| Aloui, A | 1 |
| Kaddour, RB | 1 |
| Guo, L | 2 |
| Lv, H | 1 |
| Zhong, L | 1 |
| Wu, J | 2 |
| Ding, H | 1 |
| Xu, J | 4 |
| Huang, R | 1 |
| Babayiğit, E | 1 |
| Mert, KU | 1 |
| Miyoshi, A | 1 |
| Nishii, N | 1 |
| Okamoto, Y | 1 |
| Fujita, S | 1 |
| Kawamoto, K | 1 |
| Okawa, K | 1 |
| Hiramatsu, S | 1 |
| Nakamura, K | 2 |
| Morita, H | 1 |
| Ito, H | 1 |
| Freund, Y | 2 |
| Gorlicki, J | 2 |
| Wang, K | 2 |
| Samai, K | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 6 |
| Hu, K | 2 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 5 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 3 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 6 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 5 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 2 |
| Li, X | 5 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 7 |
| Xu, N | 1 |
| Wang, R | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 3 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 2 |
| Yan, R | 1 |
| Zhang, Y | 7 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 8 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 7 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Liu, Y | 7 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 2 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 2 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 4 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 4 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 3 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 2 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 3 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 2 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 2 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 2 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 4 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 3 |
| Liu, X | 4 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 2 |
| Zhao, M | 1 |
| Hu, J | 2 |
| Yao, C | 1 |
| Zhang, B | 2 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 2 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 2 |
| Park, S | 3 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 2 |
| Vogrin, S | 1 |
| Neil, CJ | 2 |
| Allen, JD | 5 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 3 |
| Liang, H | 1 |
| Xu, X | 2 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 4 |
| Xue, H | 1 |
| Zhang, W | 1 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 2 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 2 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 4 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 2 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 2 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 2 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 2 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Gui, Y | 1 |
| Ouyang, M | 1 |
| Liu, L | 1 |
| Sun, K | 1 |
| Xiang, Q | 1 |
| Peng, Z | 1 |
| Zou, P | 1 |
| Li, B | 1 |
| Zheng, Z | 1 |
| Woessner, MN | 2 |
| McIlvenna, LC | 1 |
| Neil, C | 1 |
| Long, W | 1 |
| Liao, H | 1 |
| Ning, Y | 1 |
| Wu, T | 1 |
| Xian, S | 1 |
| Giam, B | 1 |
| Nomura, H | 1 |
| Kuruppu, S | 1 |
| Chu, PY | 1 |
| Essid, S | 1 |
| Kiriazis, H | 1 |
| Du, XJ | 1 |
| Kaye, DM | 1 |
| Rajapakse, NW | 1 |
| Coggan, AR | 4 |
| Racette, SB | 2 |
| Thies, D | 1 |
| Peterson, LR | 4 |
| Stratford, RE | 1 |
| Zhong, R | 1 |
| Bao, Y | 1 |
| Cachanado, M | 1 |
| Delannoy, Q | 1 |
| Laribi, S | 2 |
| Yordanov, Y | 1 |
| Chouihed, T | 1 |
| Féral-Pierssens, AL | 1 |
| Truchot, J | 1 |
| Desmettre, T | 1 |
| Occelli, C | 1 |
| Bobbia, X | 1 |
| Khellaf, M | 1 |
| Ganansia, O | 1 |
| Bokobza, J | 1 |
| Balen, F | 1 |
| Beaune, S | 1 |
| Bloom, B | 1 |
| Simon, T | 1 |
| Mebazaa, A | 3 |
| Wu, Z | 1 |
| Tian, T | 1 |
| Ma, W | 1 |
| Gao, W | 1 |
| Song, N | 1 |
| Ferguson, SK | 2 |
| Holmes, MJ | 1 |
| Belbis, MD | 1 |
| Carlström, M | 1 |
| Weitzberg, E | 2 |
| Hirai, DM | 2 |
| Wan, SH | 1 |
| Pandey, A | 1 |
| Ilonze, OJ | 1 |
| Guglin, M | 1 |
| Gee, LC | 1 |
| Massimo, G | 1 |
| Lau, C | 1 |
| Primus, C | 1 |
| Fernandes, D | 1 |
| Rathod, KS | 1 |
| Hamers, AJP | 1 |
| Filomena, F | 1 |
| Nuredini, G | 1 |
| Ibrahim, AS | 1 |
| Khambata, RS | 1 |
| Gupta, AK | 1 |
| Moon, JC | 1 |
| Kapil, V | 1 |
| Ahluwalia, A | 1 |
| Sharma, K | 1 |
| Kass, DA | 1 |
| Lim, SL | 1 |
| Benson, L | 1 |
| Dahlström, U | 2 |
| Lam, CS | 1 |
| Lund, LH | 1 |
| Papadimitriou, L | 1 |
| Hamo, CE | 1 |
| Butler, J | 2 |
| Reddy, YNV | 2 |
| Lewis, GD | 1 |
| Shah, SJ | 2 |
| LeWinter, M | 1 |
| Semigran, M | 1 |
| Davila-Roman, VG | 1 |
| Anstrom, K | 1 |
| Hernandez, A | 1 |
| Braunwald, E | 2 |
| Redfield, MM | 2 |
| Borlaug, BA | 3 |
| Shaltout, HA | 1 |
| Eggebeen, J | 2 |
| Marsh, AP | 1 |
| Brubaker, PH | 1 |
| Laurienti, PJ | 1 |
| Burdette, JH | 1 |
| Basu, S | 2 |
| Morgan, A | 1 |
| Dos Santos, PC | 1 |
| Norris, JL | 1 |
| Morgan, TM | 2 |
| Miller, GD | 1 |
| Rejeski, WJ | 1 |
| Hawfield, AT | 1 |
| Diz, DI | 1 |
| Becton, JT | 1 |
| Kim-Shapiro, DB | 2 |
| Kitzman, DW | 2 |
| Gilbert-Kawai, E | 1 |
| Montgomery, H | 1 |
| Andersen, MJ | 1 |
| Obokata, M | 1 |
| Koepp, KE | 1 |
| Kane, GC | 1 |
| Melenovsky, V | 1 |
| Olson, TP | 1 |
| Falls, R | 1 |
| Seman, M | 1 |
| Braat, S | 1 |
| Sortino, J | 1 |
| Patel, JN | 1 |
| Zahidova, KK | 1 |
| Chirinos, JA | 4 |
| Gladden, JD | 1 |
| Chaanine, AH | 1 |
| Londono-Hoyos, F | 1 |
| Zamani, P | 3 |
| Beraun, M | 1 |
| Vasim, I | 1 |
| Segers, P | 1 |
| Goggin, P | 1 |
| Goldstein, I | 1 |
| Hackett, G | 1 |
| Kirby, MG | 1 |
| Osterloh, I | 1 |
| Parker, JD | 4 |
| Sadovsky, R | 1 |
| Kerley, CP | 1 |
| Mulkareddy, V | 1 |
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Morant, S | 1 |
| Jiang, B | 1 |
| Cruickshank, JK | 1 |
| Webb, AJ | 2 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Zhou, F | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Hua, H | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Nagai, T | 1 |
| Iwakami, N | 1 |
| Nakai, M | 1 |
| Nishimura, K | 1 |
| Sumita, Y | 1 |
| Mizuno, A | 1 |
| Tsutsui, H | 1 |
| Ogawa, H | 1 |
| Anzai, T | 1 |
| Al-Mohammad, A | 1 |
| Tsujimoto, T | 1 |
| Kajio, H | 1 |
| Fu, S | 1 |
| Ping, P | 1 |
| Ye, P | 1 |
| Wo, D | 1 |
| Zhuang, P | 1 |
| Xu, ZG | 1 |
| Xu, S | 1 |
| Mao, HM | 1 |
| Wakai, A | 1 |
| McCabe, A | 1 |
| Kidney, R | 1 |
| Brooks, SC | 1 |
| Seupaul, RA | 1 |
| Diercks, DB | 1 |
| Salter, N | 1 |
| Fermann, GJ | 1 |
| Pospisil, C | 1 |
| Maggioni, AP | 1 |
| Anker, SD | 1 |
| Filippatos, G | 1 |
| Ponikowski, P | 1 |
| Zannad, F | 1 |
| Amir, O | 1 |
| Chioncel, O | 1 |
| Leiro, MC | 1 |
| Drozdz, J | 1 |
| Erglis, A | 1 |
| Fazlibegovic, E | 1 |
| Fonseca, C | 2 |
| Fruhwald, F | 1 |
| Gatzov, P | 1 |
| Hassanein, M | 1 |
| Hradec, J | 1 |
| Kavoliuniene, A | 1 |
| Lainscak, M | 1 |
| Logeart, D | 1 |
| Merkely, B | 1 |
| Metra, M | 2 |
| Persson, H | 1 |
| Seferovic, P | 1 |
| Temizhan, A | 1 |
| Tousoulis, D | 1 |
| Tavazzi, L | 1 |
| Tarvasmäki, T | 1 |
| Harjola, VP | 1 |
| Tolonen, J | 1 |
| Siirilä-Waris, K | 1 |
| Nieminen, MS | 1 |
| Lassus, J | 1 |
| Cotter, G | 2 |
| Davison, B | 1 |
| Gupta, D | 1 |
| Georgiopoulou, VV | 1 |
| Kalogeropoulos, AP | 1 |
| Yancy, CW | 2 |
| Gheorghiade, M | 2 |
| Fonarow, GC | 1 |
| Konstam, MA | 1 |
| Thadani, U | 3 |
| Bailey, JC | 1 |
| Feelisch, M | 1 |
| Horowitz, JD | 2 |
| Frenneaux, MP | 1 |
| Madhani, M | 1 |
| Piper, S | 1 |
| McDonagh, T | 1 |
| Turner, J | 1 |
| Kirschner, J | 1 |
| Vanderpool, R | 1 |
| Gladwin, MT | 1 |
| Rawat, D | 1 |
| Shiva-Kumar, P | 1 |
| Geraci, S | 1 |
| Bhuva, R | 1 |
| Konda, P | 1 |
| Doulias, PT | 1 |
| Ischiropoulos, H | 1 |
| Townsend, RR | 1 |
| Margulies, KB | 1 |
| Cappola, TP | 1 |
| Poole, DC | 2 |
| Herrero-Puente, P | 1 |
| Jacob, J | 1 |
| Martín-Sánchez, FJ | 1 |
| Vázquez-Álvarez, J | 1 |
| Martínez-Camblor, P | 1 |
| Miró, Ò | 1 |
| Lucas-Imbernón, FJ | 1 |
| Martínez-Zapico, A | 1 |
| Llorens, P | 1 |
| Mohan, M | 1 |
| Hawkey, S | 1 |
| Baig, F | 1 |
| Choy, AM | 1 |
| Lang, CC | 1 |
| Farag, M | 1 |
| Mabote, T | 1 |
| Shoaib, A | 1 |
| Nabhan, AF | 1 |
| Clark, AL | 2 |
| Cleland, JG | 2 |
| Leibowitz, JL | 1 |
| Spearie, CA | 1 |
| Kadkhodayan, A | 1 |
| Thomas, DP | 1 |
| Ramamurthy, S | 1 |
| Mahmood, K | 1 |
| Waller, S | 1 |
| Farmer, M | 1 |
| Aizawa, H | 1 |
| Imai, S | 1 |
| Fushimi, K | 1 |
| Omar, SA | 1 |
| Lundberg, JO | 1 |
| Ho, EC | 1 |
| Austin, PC | 1 |
| Tu, JV | 1 |
| Lee, DS | 1 |
| Haykowsky, M | 1 |
| Brubaker, P | 1 |
| Rejeski, J | 1 |
| Moreira-Silva, S | 1 |
| Urbano, J | 1 |
| Nogueira-Silva, L | 1 |
| Bettencourt, P | 1 |
| Pimenta, J | 1 |
| Parenica, J | 1 |
| Kala, P | 1 |
| Pavkova, MG | 1 |
| Tomandl, J | 1 |
| Spinar, J | 1 |
| Littnerova, S | 1 |
| Jarkovsky, J | 1 |
| Tomandlova, M | 1 |
| Dastych, M | 1 |
| Gottwaldova, J | 1 |
| Gayat, E | 2 |
| Staszewsky, L | 1 |
| Cortesi, L | 1 |
| Tettamanti, M | 1 |
| Dal Bo, GA | 1 |
| Fortino, I | 1 |
| Bortolotti, A | 1 |
| Merlino, L | 1 |
| Latini, R | 1 |
| Roncaglioni, MC | 1 |
| Baviera, M | 1 |
| Roizen, MF | 1 |
| Alsop, P | 1 |
| Hauton, D | 1 |
| Holdsworth, CT | 1 |
| Colburn, TD | 1 |
| Wright, JL | 1 |
| Craig, JC | 1 |
| Fees, A | 1 |
| Jones, AM | 1 |
| Musch, TI | 1 |
| Richardson, A | 1 |
| Tolley, E | 1 |
| Hartmann, J | 1 |
| Reedus, J | 1 |
| Bowlin, B | 1 |
| Finch, C | 1 |
| Sands, CW | 1 |
| Self, T | 1 |
| Zelt, JT | 1 |
| Castanhas, LG | 1 |
| Earle, W | 1 |
| Staples, P | 1 |
| Tschakovsky, ME | 1 |
| McCans, J | 1 |
| O'Donnell, DE | 1 |
| Neder, JA | 1 |
| Joyce, E | 1 |
| Givertz, MM | 1 |
| Stewart, GC | 1 |
| Kittleson, MM | 1 |
| Patel, PC | 1 |
| Cowger, JA | 1 |
| Patel, CB | 1 |
| Mountis, MM | 1 |
| Johnson, FL | 1 |
| Guglin, ME | 1 |
| Rame, JE | 1 |
| Teuteberg, JJ | 1 |
| Stevenson, LW | 1 |
| Wani-Parekh, P | 1 |
| Blanco-Garcia, C | 1 |
| Mendez, M | 1 |
| Mukherjee, D | 1 |
| Keijzers, G | 1 |
| Kelly, AM | 1 |
| Cullen, L | 1 |
| Klim, S | 1 |
| Graham, CA | 1 |
| Craig, S | 1 |
| Kuan, WS | 1 |
| Jones, P | 1 |
| Holdgate, A | 1 |
| Lawoko, C | 1 |
| Honoré, JC | 1 |
| Carrier, E | 1 |
| Fecteau, MH | 1 |
| Tirapelli, CR | 1 |
| Bkaily, G | 1 |
| D'Orleans-Juste, P | 1 |
| Goebel, JA | 1 |
| Van Bakel, AB | 1 |
| Münzel, T | 2 |
| Teerlink, JR | 1 |
| Voors, AA | 1 |
| Felker, GM | 1 |
| Milo-Cotter, O | 1 |
| Weatherley, B | 1 |
| Dittrich, H | 1 |
| Riccioni, G | 1 |
| Vitulano, N | 1 |
| D'Orazio, N | 1 |
| Pfisterer, M | 1 |
| Buser, P | 1 |
| Rickli, H | 1 |
| Gutmann, M | 1 |
| Erne, P | 1 |
| Rickenbacher, P | 1 |
| Vuillomenet, A | 1 |
| Jeker, U | 1 |
| Dubach, P | 1 |
| Beer, H | 1 |
| Yoon, SI | 1 |
| Suter, T | 1 |
| Osterhues, HH | 1 |
| Schieber, MM | 1 |
| Hilti, P | 1 |
| Schindler, R | 1 |
| Brunner-La Rocca, HP | 1 |
| Laurent, M | 1 |
| Daline, T | 1 |
| Malika, B | 1 |
| Fawzi, O | 1 |
| Philippe, V | 1 |
| Benoit, D | 1 |
| Catherine, M | 1 |
| Jacques, R | 1 |
| Lisi, M | 1 |
| Gori, T | 2 |
| Breidthardt, T | 1 |
| Noveanu, M | 1 |
| Potocki, M | 1 |
| Reichlin, T | 1 |
| Egli, P | 1 |
| Hartwiger, S | 1 |
| Socrates, T | 1 |
| Christ, M | 1 |
| Mueller, C | 1 |
| Morf, S | 1 |
| Hochuli, M | 1 |
| Elke, B | 1 |
| Pfister, O | 1 |
| Sato, Y | 1 |
| Nishi, K | 1 |
| Saijo, S | 1 |
| Tanada, Y | 1 |
| Goto, T | 1 |
| Takahashi, N | 2 |
| Yamamoto, E | 1 |
| Fukuhara, R | 1 |
| Miyamoto, T | 1 |
| Taniguchi, R | 1 |
| Fujiwara, H | 1 |
| Takatsu, Y | 1 |
| Doroszko, A | 1 |
| Polewicz, D | 1 |
| Cadete, VJ | 1 |
| Sawicka, J | 1 |
| Jones, M | 1 |
| Szczesna-Cordary, D | 1 |
| Cheung, PY | 1 |
| Sawicki, G | 1 |
| Gray, A | 1 |
| Goodacre, S | 1 |
| Seah, M | 1 |
| Tilley, S | 1 |
| Heusch, P | 1 |
| Aker, S | 1 |
| Boengler, K | 1 |
| Deindl, E | 1 |
| van de Sand, A | 1 |
| Klein, K | 1 |
| Rassaf, T | 1 |
| Konietzka, I | 1 |
| Sewell, A | 1 |
| Menazza, S | 1 |
| Canton, M | 1 |
| Heusch, G | 1 |
| Di Lisa, F | 1 |
| Schulz, R | 5 |
| Daiber, A | 1 |
| Erdmann, E | 1 |
| Spanheimer, R | 1 |
| Charbonnel, B | 1 |
| Bellisarii, FI | 1 |
| Muscente, F | 1 |
| Radico, F | 1 |
| Appignani, M | 1 |
| De Caterina, R | 1 |
| Siervo, M | 1 |
| Jackson, SJ | 1 |
| Bluck, LJ | 1 |
| Jacoby, D | 1 |
| Albajrami, O | 1 |
| Bellumkonda, L | 1 |
| Bongartz, LG | 1 |
| Joles, JA | 1 |
| Verhaar, MC | 1 |
| Cramer, MJ | 1 |
| Goldschmeding, R | 1 |
| Tilburgs, C | 1 |
| Gaillard, CA | 1 |
| Doevendans, PA | 1 |
| Braam, B | 1 |
| Custodis, F | 1 |
| Laufs, U | 2 |
| Shahzad, A | 1 |
| Powell, C | 1 |
| Etherington, R | 1 |
| Somauroo, J | 1 |
| Vizzardi, E | 1 |
| Bonadei, I | 1 |
| Rovetta, R | 1 |
| D'Aloia, A | 1 |
| Quinzani, F | 1 |
| Curnis, A | 1 |
| Dei Cas, L | 1 |
| Sugamori, T | 1 |
| Ishibashi, Y | 1 |
| Shimada, T | 1 |
| Sakane, T | 1 |
| Ohata, S | 1 |
| Kunizawa, Y | 1 |
| Inoue, S | 1 |
| Ohta, Y | 1 |
| Shimizu, H | 1 |
| Katoh, H | 1 |
| Oyake, N | 1 |
| Murakami, Y | 1 |
| Hashimoto, M | 1 |
| Bouvy, ML | 1 |
| Heerdink, ER | 1 |
| Leufkens, HG | 1 |
| Hoes, AW | 1 |
| Zile, MR | 1 |
| Gnanasegaram, D | 1 |
| Argall, J | 1 |
| WILES, HB | 1 |
| Levine, TB | 1 |
| Levine, AB | 1 |
| Bolenbaugh, J | 1 |
| Green, PR | 1 |
| Iwanaga, Y | 1 |
| Gu, Y | 1 |
| Dieterle, T | 1 |
| Presotto, C | 1 |
| Del Soldato, P | 1 |
| Peterson, KL | 1 |
| Ongini, E | 1 |
| Condorelli, G | 1 |
| Ross, J | 1 |
| Ergin, A | 1 |
| Eryol, NK | 1 |
| Unal, S | 1 |
| Deliceo, A | 1 |
| Topsakal, R | 1 |
| Seyfeli, E | 1 |
| Nicholls, C | 1 |
| Sani, M | 1 |
| Rywik, TM | 1 |
| Rywik, SL | 1 |
| Korewicki, J | 1 |
| Broda, G | 1 |
| Sarnecka, A | 1 |
| Drewla, J | 1 |
| Goyal, D | 1 |
| Choudhary, A | 1 |
| Lip, GY | 1 |
| MacFadyen, RJ | 1 |
| Tepliakov, AT | 1 |
| Debirov, MM | 1 |
| Bolotskaia, LA | 1 |
| Stepacheva, TA | 1 |
| Rybal'chenko, EV | 1 |
| Karaman, NV | 1 |
| Bitar, F | 1 |
| Akhter, MW | 1 |
| Khan, S | 1 |
| Singh, H | 1 |
| Elkayam, U | 5 |
| Lam, CF | 1 |
| Croatt, AJ | 1 |
| Richardson, DM | 1 |
| Nath, KA | 1 |
| Katusic, ZS | 1 |
| Román-Sánchez, P | 1 |
| Conthe, P | 1 |
| García-Alegría, J | 1 |
| Forteza-Rey, J | 1 |
| Montero, M | 1 |
| Montoto, C | 1 |
| Niebauer, J | 1 |
| Webb-Peploe, KM | 1 |
| Böger, R | 1 |
| Coats, AJ | 1 |
| O'Connor, CM | 1 |
| Stough, WG | 1 |
| Gallup, DS | 1 |
| Hasselblad, V | 1 |
| Capomolla, S | 1 |
| Ceresa, M | 1 |
| Pinna, G | 1 |
| Maestri, R | 1 |
| La Rovere, MT | 1 |
| Febo, O | 1 |
| Rossi, A | 1 |
| Paganini, V | 1 |
| Caporotondi, A | 1 |
| Guazzotti, G | 1 |
| Gnemmi, M | 1 |
| Mortara, A | 1 |
| Cobelli, F | 1 |
| Sturm, HB | 1 |
| van Gilst, WH | 1 |
| Swedberg, K | 4 |
| Hobbs, FD | 1 |
| Haaijer-Ruskamp, FM | 1 |
| Nissen, SE | 1 |
| Folkeringa, RJ | 1 |
| Van Kraaij, DJ | 1 |
| Tieleman, RG | 1 |
| Nieman, FH | 1 |
| Pinto, YM | 1 |
| Crijns, HJ | 1 |
| Field, K | 1 |
| Ziebland, S | 1 |
| McPherson, A | 1 |
| Lehman, R | 1 |
| Schüpfer, CA | 1 |
| Parodi, O | 1 |
| De Maria, R | 1 |
| Roubina, E | 1 |
| Janmohamed, M | 1 |
| Habib, M | 1 |
| Hatamizadeh, P | 1 |
| Heywood, JT | 1 |
| Khan, TA | 1 |
| Susic, D | 1 |
| Frohlich, ED | 1 |
| Opie, LH | 4 |
| Harris, PJ | 1 |
| Lee, KL | 1 |
| Harrell, FE | 1 |
| Behar, VS | 1 |
| Rosati, RA | 1 |
| Beaune, J | 1 |
| Terry, RW | 1 |
| Koller, H | 1 |
| Prager, H | 1 |
| Heinecker, R | 1 |
| Golochevskaia, VS | 1 |
| Simoons, ML | 1 |
| Serruys, PW | 1 |
| Fioretti, P | 1 |
| van den Brand, M | 1 |
| Hugenholtz, PG | 1 |
| Hoekenga, D | 1 |
| Abrams, J | 13 |
| Sterz, H | 1 |
| Kronik, G | 1 |
| Ochs, HR | 1 |
| Bodem, G | 1 |
| Colucci, WS | 1 |
| Williams, GH | 1 |
| Alexander, RW | 1 |
| Rudolf, W | 1 |
| Froer, KL | 1 |
| Hall, D | 2 |
| Schwartz, AB | 1 |
| Chatterjee, K | 6 |
| Larbig, D | 1 |
| Nasse, H | 1 |
| Sjögren, A | 2 |
| Demma, FJ | 1 |
| Wilson, RR | 1 |
| Smith, ER | 1 |
| Smiseth, OA | 1 |
| Kingma, I | 1 |
| Manyari, D | 1 |
| Belenkie, I | 1 |
| Tyberg, JV | 1 |
| Timmis, AD | 1 |
| Richardson, PJ | 1 |
| Samiev, UB | 1 |
| Delius, W | 1 |
| Parmley, WW | 1 |
| Lhoste, F | 1 |
| Massie, B | 1 |
| Ports, T | 1 |
| Parmley, W | 1 |
| Ostland, J | 1 |
| O'Young, J | 1 |
| Haughom, F | 1 |
| Martynov, AI | 1 |
| Belinskaia, TF | 1 |
| Khomenko, VL | 1 |
| Pomerantsev, VP | 1 |
| Vasiuk, IuA | 1 |
| Franciosa, JA | 5 |
| Pierpont, G | 1 |
| Gould, L | 1 |
| Reddy, CV | 1 |
| Zen, B | 1 |
| Singh, BK | 1 |
| Dipalma, JR | 1 |
| Mandell, HN | 1 |
| Deglin, SM | 1 |
| Rutishauser, W | 1 |
| Packer, M | 4 |
| Armstrong, PW | 4 |
| Moffat, JA | 1 |
| Rouleau, JL | 1 |
| Massie, BM | 1 |
| Serbin, VI | 1 |
| Gasanova, AS | 1 |
| Gilfrich, HJ | 1 |
| Hernandez, J | 1 |
| Owens, CW | 1 |
| Schlup, P | 2 |
| Mattern, HJ | 1 |
| Bolte, HD | 1 |
| Bussmann, WD | 1 |
| Segal, BL | 1 |
| Cabaniss, CD | 1 |
| Weiss, G | 1 |
| Umlauft, F | 1 |
| Grünewald, K | 1 |
| Gorlin, R | 1 |
| Koifman, B | 1 |
| Wollman, Y | 1 |
| Bogomolny, N | 1 |
| Chernichowsky, T | 1 |
| Finkelstein, A | 1 |
| Peer, G | 1 |
| Scherez, J | 1 |
| Blum, M | 1 |
| Laniado, S | 1 |
| Iaina, A | 1 |
| Giles, TD | 1 |
| Winlaw, DS | 2 |
| Smythe, GA | 2 |
| Keogh, AM | 2 |
| Schyvens, CG | 2 |
| Spratt, PM | 2 |
| Macdonald, PS | 2 |
| Myhre, ES | 1 |
| Gundersen, T | 1 |
| Dickstein, K | 1 |
| Hole, T | 1 |
| Kjekshus, J | 1 |
| Rønnevik, P | 1 |
| Smith, P | 1 |
| Westheim, A | 1 |
| Torfgård, KE | 1 |
| Ahlner, J | 1 |
| Fung, HL | 1 |
| Bauer, JA | 2 |
| Dupuis, J | 1 |
| Unger, P | 1 |
| Vachiery, JL | 1 |
| de Cannière, D | 1 |
| Staroukine, M | 1 |
| Berkenboom, G | 1 |
| Faggiano, P | 1 |
| Rusconi, C | 1 |
| Ghizzoni, G | 1 |
| Reynen, K | 1 |
| Devereux, RB | 1 |
| Corbalán, R | 1 |
| Kunstmann, S | 1 |
| Jalil, J | 1 |
| Bordalo e Sá, AL | 2 |
| Cohn, JN | 8 |
| Northridge, D | 1 |
| Kelly, RA | 1 |
| Smith, TW | 1 |
| Katz, AM | 1 |
| Perrenoud, JJ | 1 |
| Strasser, RH | 1 |
| Ishikawa, K | 2 |
| Kanamasa, K | 2 |
| Ogawa, I | 1 |
| Takenaka, T | 2 |
| Naito, T | 1 |
| Kamata, N | 1 |
| Yamamoto, T | 1 |
| Nakai, S | 1 |
| Hama, J | 1 |
| Oyaizu, M | 1 |
| Kimura, A | 2 |
| Yamamoto, K | 1 |
| Aso, N | 1 |
| Arai, M | 1 |
| Yabushita, H | 1 |
| Katori, Y | 1 |
| Campa, PP | 1 |
| Puddu, PE | 1 |
| Schiariti, M | 1 |
| Monti, F | 1 |
| Dawodu, AA | 1 |
| Gentile, C | 1 |
| Lilla Della Monica, PL | 1 |
| Vaccaro, M | 1 |
| De Biase, L | 1 |
| Guazzi, MD | 1 |
| Ledda, F | 1 |
| Geraci, E | 1 |
| Branzi, A | 1 |
| Filardi, PP | 1 |
| Chiariello, M | 1 |
| Mazzotta, G | 1 |
| Seghaye, MC | 1 |
| Duchateau, J | 1 |
| Bruniaux, J | 1 |
| Demontoux, S | 1 |
| Détruit, H | 1 |
| Bosson, C | 1 |
| Lecronier, G | 1 |
| Mokhfi, E | 1 |
| Serraf, A | 1 |
| Planché, C | 1 |
| Blasini, R | 1 |
| Lehmann, G | 1 |
| Schömig, A | 1 |
| Khadour, FH | 2 |
| Kao, RH | 1 |
| Holycross, BJ | 1 |
| Bernstein, RD | 1 |
| Zhao, G | 1 |
| Forfia, P | 1 |
| Tuzman, J | 1 |
| Ochoa, F | 1 |
| Ochoa, M | 2 |
| Vogel, T | 2 |
| Hintze, TH | 2 |
| Watanabe, H | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| Preiser, JC | 1 |
| De Backer, D | 1 |
| Debelle, F | 1 |
| Vray, B | 1 |
| Vincent, JL | 1 |
| Carville, C | 1 |
| Adnot, S | 1 |
| Sediame, S | 1 |
| Benacerraf, S | 1 |
| Castaigne, A | 1 |
| Calvo, F | 1 |
| de Cremou, P | 1 |
| Dubois-Randé, JL | 1 |
| O'Brien, DW | 1 |
| Fu, Y | 1 |
| Nickenig, G | 1 |
| Wassmann, S | 1 |
| Böhm, M | 2 |
| Flesch, M | 1 |
| Kilter, H | 1 |
| Cremers, B | 1 |
| Südkamp, M | 1 |
| Ortmann, M | 1 |
| Müller, FU | 1 |
| Katz, SD | 1 |
| Khan, T | 1 |
| Zeballos, GA | 1 |
| Mathew, L | 1 |
| Potharlanka, P | 1 |
| Knecht, M | 1 |
| Whelan, J | 1 |
| Soeki, T | 1 |
| Fukuda, N | 1 |
| Shinohara, H | 1 |
| Takeichi, N | 1 |
| Tanaka, H | 1 |
| Bando, K | 1 |
| Yui, Y | 1 |
| Tamura, Y | 1 |
| Bauersachs, J | 1 |
| Bouloumié, A | 1 |
| Fraccarollo, D | 1 |
| Busse, R | 1 |
| Ertl, G | 1 |
| Feng, Q | 1 |
| Fortin, AJ | 1 |
| Arnold, JM | 1 |
| Arnold, O | 1 |
| Werdan, K | 1 |
| Scardi, S | 1 |
| Mazzone, C | 1 |
| Lovell, SL | 1 |
| Stevenson, H | 1 |
| Young, IS | 1 |
| McDowell, G | 1 |
| McEneaney, D | 1 |
| Riley, MS | 1 |
| Nicholls, DP | 1 |
| Clini, E | 1 |
| Volterrani, M | 1 |
| Pagani, M | 1 |
| Bianchi, L | 1 |
| Porta, R | 1 |
| Gile', LS | 1 |
| Giordano, A | 1 |
| Ambrosino, N | 1 |
| Prior, DL | 1 |
| Chin-Dusting, JP | 1 |
| Ferdinandy, P | 1 |
| Danial, H | 1 |
| Ambrus, I | 1 |
| Rothery, RA | 1 |
| Forte, P | 1 |
| Benjamin, N | 1 |
| Murdoch, DR | 1 |
| McMurray, JJ | 1 |
| Osorio, JC | 1 |
| Laycock, S | 1 |
| Mihm, MJ | 1 |
| Coyle, CM | 1 |
| Schanbacher, BL | 1 |
| Weinstein, DM | 1 |
| Hollerbach, S | 1 |
| Schultze, K | 1 |
| Muscholl, M | 1 |
| Schölmerich, J | 1 |
| Hayashi, T | 1 |
| Ikeda, A | 1 |
| Johnson, A | 1 |
| Mackway-Jones, K | 1 |
| John, J | 1 |
| Dhawan, J | 1 |
| Clark, A | 1 |
| Chowdhary, S | 1 |
| Ng, GA | 1 |
| Nuttall, SL | 1 |
| Coote, JH | 1 |
| Ross, HF | 1 |
| Townend, JN | 1 |
| de Denus, S | 1 |
| Spinler, SA | 1 |
| Saito, T | 1 |
| Hu, F | 1 |
| Tayara, L | 1 |
| Fahas, L | 1 |
| Shennib, H | 1 |
| Giaid, A | 1 |
| Warren, SE | 1 |
| Francis, GS | 1 |
| Bertel, O | 2 |
| Baitsch, G | 2 |
| Elsässer, S | 1 |
| Ritz, R | 2 |
| Burkart, F | 2 |
| Mathey, D | 1 |
| Aronow, WS | 1 |
| Brundage, BH | 1 |
| Ports, TA | 1 |
| Mah, PK | 1 |
| Halawa, B | 1 |
| Plotnick, GD | 1 |
| Greene, HL | 1 |
| Carliner, NH | 1 |
| Becker, LC | 1 |
| Fisher, ML | 1 |
| Lloyd, EA | 1 |
| Bonchek, LI | 1 |
| Olinger, GN | 1 |
| Keelan, MH | 1 |
| Tresch, DD | 1 |
| Siegel, R | 1 |
| Miller, RR | 2 |
| Awan, NA | 1 |
| Mason, DT | 2 |
| Meller, J | 1 |
| Vyden, JK | 1 |
| Takano, TT | 1 |
| Rose, HB | 1 |
| Ogawa, T | 1 |
| Awan, N | 1 |
| Amsterdam, EA | 1 |
| Jasiński, K | 1 |
| Poprawski, K | 1 |
| Steiner, A | 1 |
| Vettiger, K | 1 |
| Blank, RC | 1 |
| Chiche, P | 1 |
| Baligadoo, S | 1 |
| Barritault, L | 1 |
| Portaluppi, F | 1 |
| Montanari, L | 1 |
| Ferlini, M | 1 |
| Vergnani, L | 1 |
| Bagni, B | 1 |
| Degli Uberti, EC | 1 |
| Held, P | 2 |
| Rosenqvist, M | 1 |
| Rydén, L | 2 |
| Mehra, A | 1 |
| Shotan, A | 1 |
| Ostrzega, E | 1 |
| Kleber, FX | 1 |
| Niemöller, L | 1 |
| Fischer, M | 1 |
| Doering, W | 1 |
| Rudolph, W | 3 |
| Dirschinger, J | 3 |
| Mohan, P | 1 |
| Hii, JT | 1 |
| Wuttke, RD | 1 |
| Esterman, AJ | 1 |
| Hollington, P | 1 |
| Shushliapin, OI | 1 |
| Shelest, AN | 1 |
| Khosseĭn Shakhavat, AF | 1 |
| Marin-Neto, JA | 1 |
| Pintya, AO | 1 |
| Gallo Júnior, L | 1 |
| Maciel, BC | 1 |
| Negrescu, EV | 1 |
| Sazonova, LN | 1 |
| Baldenkov, GN | 1 |
| Mukharliamov, NM | 1 |
| Mazaev, AV | 1 |
| Tkachuk, VA | 1 |
| Costa, R | 1 |
| Marino, A | 1 |
| Assmann, I | 1 |
| Remme, WJ | 1 |
| Engelmann, L | 1 |
| Wetzler, G | 1 |
| Kucher, A | 1 |
| Frömmel, H | 1 |
| Weber, S | 1 |
| Herman, BM | 1 |
| Charlap, S | 1 |
| Frishman, WH | 1 |
| Heikkilä, J | 1 |
| Srebro, J | 1 |
| Karliner, JS | 1 |
| Goldsmith, SR | 1 |
| Marx, S | 1 |
| Leier, CV | 1 |
| Mirrakhimov, MM | 1 |
| Moldotashev, IK | 1 |
| Kadyraliev, KK | 1 |
| Ruggie, N | 1 |
| Taylor, SH | 1 |
| Zeller, FP | 1 |
| Klamerus, KJ | 1 |
| Koczwara, A | 1 |
| Sroczyński, J | 1 |
| Podolecki, A | 1 |
| Schneiberg, P | 1 |
| Burak, W | 1 |
| Biskupek, K | 1 |
| Sutton, FJ | 1 |
| Conradson, TB | 1 |
| Batlouni, M | 1 |
| Ollagnier, M | 1 |
| Vlay, SC | 1 |
| Cohn, PF | 1 |
| Beck, OA | 1 |
| Lehmann, HU | 1 |
| Hochrein, H | 1 |
| Nager, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| National, Prospective, Multicenter,Observational Registry Study on Pulmonary Hypertension Due to Left Heart Disease in China[NCT02164526] | 520 participants (Anticipated) | Observational [Patient Registry] | 2013-01-31 | Recruiting | |||
| Early and Comprehensive Care Bundle in Elderly for Acute Heart Failure: a Stepped Wedge Cluster Randomized Trial[NCT03683212] | 503 participants (Actual) | Interventional | 2018-12-10 | Completed | |||
| Effect of Short-Term Prednisone Therapy on C-reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers[NCT05916586] | 120 participants (Anticipated) | Interventional | 2023-08-11 | Recruiting | |||
| Nitrite Supplementation to Mitigate Fatigability and Increase Function in Long COVID Patients[NCT05618574] | Phase 3 | 40 participants (Anticipated) | Interventional | 2023-12-01 | Recruiting | ||
| Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF[NCT02742129] | Phase 2 | 105 participants (Actual) | Interventional | 2016-08-10 | Completed | ||
| Effects of Relaxation Breathing Exercises on Cardiovascular Parameters Among Hypertensive Patients[NCT06131528] | 40 participants (Anticipated) | Interventional | 2023-10-30 | Recruiting | |||
| A Multicenter Randomized Controlled Trial of Exercise in Aortic Dissection Survivors[NCT05610462] | 126 participants (Anticipated) | Interventional | 2023-01-01 | Active, not recruiting | |||
| Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction[NCT03837470] | Early Phase 1 | 14 participants (Actual) | Interventional | 2019-05-06 | Completed | ||
| The Effect of NO Precursors on Physiological Responses to Exercise[NCT02850367] | 63 participants (Actual) | Interventional | 2016-05-09 | Completed | |||
| A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension[NCT01431313] | Phase 2 | 48 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Effect of Inorganic Nitrates on Arterial Hemodynamics and Exercise Capacity[NCT01919177] | Phase 2 | 17 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure With Preserved Ejection Fraction (BLOCK HFpEF) Trial[NCT04434664] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Clinical and Genetic Determinants of Disease Progression and Response to Lifestyle and Pharmacological Interventions in Patients With Hypertrophic Cardiomyopathy[NCT05366101] | Phase 2/Phase 3 | 168 participants (Actual) | Interventional | 2019-04-01 | Completed | ||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy[NCT03832660] | Phase 2 | 168 participants (Actual) | Interventional | 2019-05-03 | Completed | ||
| Dietary Nitrates for Heart Failure[NCT01682356] | Phase 1/Phase 2 | 126 participants (Anticipated) | Interventional | 2012-01-31 | Active, not recruiting | ||
| Dietary Nitrate and Muscle Power With Aging[NCT03513302] | 20 participants (Actual) | Interventional | 2019-03-01 | Completed | |||
| Dose-response Effect of Dietary Nitrate on Muscle Function in Older Individuals[NCT03595774] | Phase 1 | 13 participants (Actual) | Interventional | 2018-09-01 | Completed | ||
| Treatment of HFpEF With Nitrate Supplement: A Double-blind, Placebo Controlled Trial Including Patients With Atrial Fibrillation[NCT03289481] | Early Phase 1 | 13 participants (Actual) | Interventional | 2017-06-29 | Completed | ||
| Dietary Nitrate Supplementation and Thermoregulation During Exercise[NCT03506646] | 10 participants (Anticipated) | Interventional | 2018-09-05 | Active, not recruiting | |||
| The Effects of Chronic Dietary Nitrate Supplementation on Constant Work Rate Exercise in High Functioning Middle Aged and Older Adults[NCT03371966] | 29 participants (Actual) | Interventional | 2017-12-13 | Completed | |||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Effect of Oral Supplementation With One Form of L-arginine on Vascular Endothelial Function in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.[NCT02354794] | 36 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.[NCT02352740] | 32 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure[NCT01216670] | 18 participants (Actual) | Observational | 2011-02-28 | Completed | |||
| Comparative Evaluation of the Evolution of Emerging Biological Markers (sST2, Copeptin, Chromogranin, NGAL, suPAR and Cystatin) in Patients Hospitalized for Acute Heart Failure (AHF) Depending on Their Management: Conventional or Therapeutic Adjustment Ac[NCT05297630] | 169 participants (Actual) | Observational | 2022-02-15 | Completed | |||
| Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial[NCT05450328] | Phase 2 | 141 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| A Randomized Study of Pocket Ultrasound Derived IVC Diameter for Guided Management of Heart Failure[NCT01962688] | 37 participants (Actual) | Interventional | 2013-08-31 | Terminated (stopped due to low enrollment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Average arbitrary accelerometer units (AAU) during at least 14 days and up to 21 days of the maximally tolerated dose of study drug (from 28 days post Study Visit 1 until Study Visit 2 and from 28 days post Study Visit 2 until Study Visit 3). An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based upon patient movement. Higher values indicate more movement. Zero indicates no movement. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | accelerometry units (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 5692 | 5688 |
| Placebo Crossover to AIR001 | 5341 | 5289 |
To evaluate whether AR001 improves quality of life in comparison to placebo. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life). Higher values of the overall KCCQ score are considered to be better than lower values. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 65.6 | 64.1 |
| Placebo Crossover to AIR001 | 59.8 | 59.4 |
To evaluate whether AIR001 improves Left atrial volume index in comparison to placebo. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | ml/m^2 (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 36.3 | 37.2 |
| Placebo Crossover to AIR001 | 40.1 | 39.1 |
To evaluate whether AIR001 improves Medial E/e' ratio (the ratio between early mitral inflow velocity and mitral annular early diastolic velocity for diastolic evaluation) in comparison to placebo. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | ratio (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 15.4 | 15.0 |
| Placebo Crossover to AIR001 | 18.3 | 17.4 |
Evaluate whether AIR001 improves natriuretic peptide levels in comparison to placebo (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 494.8 | 513.9 |
| Placebo Crossover to AIR001 | 550.4 | 545.2 |
Self-reported participant preference for study period 1 (Phase 1) vs. study period 2 (Phase 2) (NCT02742129)
Timeframe: End of Phase 2
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Phase 1 Patient Felt Better | Phase 2 Patient Felt Better | No Preference | |
| AIR001 Crossover to Placebo | 23 | 17 | 8 |
| Placebo Crossover to AIR001 | 15 | 20 | 12 |
The primary endpoint will be the peak VO2 after 4 weeks treatment with inorganic nitrite as compared to the peak VO2 after 4 weeks treatment with placebo as assessed by cardiopulmonary exercise testing (CPET) performed at peak drug levels. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 13.4 | 13.7 |
| Placebo Crossover to AIR001 | 13.8 | 13.6 |
To evaluate whether AIR001 improves pulmonary artery systolic pressure in comparison to placebo. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | mmHg (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 38.2 | 35.0 |
| Placebo Crossover to AIR001 | 39.6 | 37.3 |
To evaluate whether ARI001 in comparison to placebo improves ventilator efficiency as measured by Slope of Ve/VCO2 during study drug administration. The Ve/VCO2 slope is defined as the slope of the linear relationship between ventilation and carbon dioxide output and is a measure of the velocity. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | unitless (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 31.8 | 32.1 |
| Placebo Crossover to AIR001 | 33.9 | 33.6 |
To evaluate whether ARI001 in comparison to placebo improves submaximal exercise capacity as measured by VO2 (rate of oxygen consumption measured during incremental exercise) at ventilatory threshold during study drug administration. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | ml/min (Mean) | |
|---|---|---|
| Phase 1 | Phase 2 | |
| AIR001 Crossover to Placebo | 7.8 | 7.9 |
| Placebo Crossover to AIR001 | 8.0 | 7.8 |
To evaluate whether AR001 improves NYHA Class in comparison to placebo. NYHA class was measured at the end of each phase. The site physician evaluated the patient based upon the criteria for NYHA class I-IV used by the American Heart Association. NYHA functional classification provides a way of classifying the extent of heart failure. Class I (least severe): No limitation of physical activity; Class II: Slight limitation of physical activity; Class III: Marked limitation of physical activity; Class IV (most severe): Unable to carry on any physical activity without discomfort. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 172157333 | Phase 172157332 | Phase 272157333 | Phase 272157332 | |||||||||||||
| I | II | III | IV | |||||||||||||
| AIR001 Crossover to Placebo | 1 | |||||||||||||||
| AIR001 Crossover to Placebo | 21 | |||||||||||||||
| Placebo Crossover to AIR001 | 29 | |||||||||||||||
| AIR001 Crossover to Placebo | 26 | |||||||||||||||
| Placebo Crossover to AIR001 | 20 | |||||||||||||||
| AIR001 Crossover to Placebo | 0 | |||||||||||||||
| Placebo Crossover to AIR001 | 1 | |||||||||||||||
| Placebo Crossover to AIR001 | 22 | |||||||||||||||
| AIR001 Crossover to Placebo | 24 | |||||||||||||||
| Placebo Crossover to AIR001 | 25 | |||||||||||||||
| Placebo Crossover to AIR001 | 0 | |||||||||||||||
Basal platelet oxygen consumption measured in isolated platelets by extracellular flux analysis (XF24, Seahorse Biosciences, Billerica, MA). (NCT01431313)
Timeframe: Maximal effect at 15 minutes post 45mg or 90mg inhalation vs Pre dose
| Intervention | picomoles O2/min (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -17.58 |
| WHO Group II Pulmonary Hypertension (PH) | 8.62 |
| WHO Group III Pulmonary Hypertension (PH) | -11.64 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of plasma nitrite concentrations in mixed venous blood over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.9 |
| WHO Group II Pulmonary Hypertension (PH) | 7.0 |
| WHO Group III Pulmonary Hypertension (PH) | 7.4 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of pulmonary artery occlusion (capillary) pullback nitrite concentration over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.2 |
| WHO Group III Pulmonary Hypertension (PH) | 2.4 |
Characteristic impedance (Zc) which may be related to compliance effects in the large, conduit arteries. (NCT01431313)
Timeframe: Pre dose and 60 minutes post last dosage inhaled
| Intervention | dyne*sec/cm5 (Median) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.004 |
| WHO Group II Pulmonary Hypertension (PH) | -0.34 |
| WHO Group III Pulmonary Hypertension (PH) | -0.20 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since pulmonary vascular resistance (PVR) was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of PVR over all subsequent times and doses (beta from the mixed effects model, converted back from natural log to Woods units), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | Woods units (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 0.77 |
| WHO Group II Pulmonary Hypertension (PH) | 0.40 |
| WHO Group III Pulmonary Hypertension (PH) | -0.39 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of MAP over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -5.1 |
| WHO Group II Pulmonary Hypertension (PH) | -3.4 |
| WHO Group III Pulmonary Hypertension (PH) | -9.5 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since systemic vascular resistance was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of SVR over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg⋅min/L (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.43 |
| WHO Group II Pulmonary Hypertension (PH) | 1.19 |
| WHO Group III Pulmonary Hypertension (PH) | -2.04 |
Time in minutes to maximum PVR decrease. During study procedure, hemodynamics were measured at 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose. The time point at which each patient's maximal decrease in PVR occurred was recorded and reported as the mean and standard deviation in each cohort. (NCT01431313)
Timeframe: 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose
| Intervention | minutes (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 42.0 |
| WHO Group II Pulmonary Hypertension (PH) | 33.0 |
| WHO Group III Pulmonary Hypertension (PH) | 42.5 |
change in E/E prime on exercise echo (E/E prime is a ratio between early mitral inflow velocity and mitral annular early diastolic velocity in order to measure diastolic dysfunction) (NCT03289481)
Timeframe: after one week of active lozenges compared to one week of placebo lozenges
| Intervention | ratio (Mean) |
|---|---|
| Active Lozenge | 1.93 |
| Placebo Lozenge | -.05 |
change in estimated right ventricular systolic pressure on echo (NCT03289481)
Timeframe: after one week of active lozenges compared to one week of placebo lozenges
| Intervention | mmHg (Mean) |
|---|---|
| Active Lozenge | 11.79 |
| Placebo | 8.6 |
change in metabolic equivalents on treadmill (NCT03289481)
Timeframe: after one week of active lozenges compared to one week of placebo lozenges
| Intervention | cal/min (Mean) |
|---|---|
| Active Lozenge | 7.99 |
| Placebo | 8.46 |
change in total time traveled on treadmill (NCT03289481)
Timeframe: after one week of active lozenges compared to one week of placebo lozenges
| Intervention | seconds (Mean) |
|---|---|
| Active Lozenge | 402.8 |
| Placebo | 181.2 |
hospitalization information will be recorded throughout the length of the study for the outpatient arms (NCT01962688)
Timeframe: up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Handheld Ultrasound | 4 |
| Clinical Assessment Only | 5 |
hospitalization information will be recorded throughout the length of the study for the inpatient arms (NCT01962688)
Timeframe: up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Handheld Ultrasound | 6 |
| Clinical Assessment Only | 18 |
"New York Heart Association (NYHA) Classification Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.~Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.~Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100m). Comfortable only at rest.~Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients." (NCT01962688)
Timeframe: 6 months
| Intervention | visits (Number) | |||
|---|---|---|---|---|
| NYHA Class I | NYHA Class II | NYHA Class III | NYHA Class IV | |
| Clinical Assessment Only | 1 | 18 | 39 | 2 |
| Handheld Ultrasound | 0 | 9 | 22 | 0 |
122 reviews available for nitrates and Heart Failure
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Efficacy and Safety of Inorganic Nitrate Versus Placebo Treatment in Heart Failure with Preserved Ejection Fraction.
Topics: Aged; Cardiovascular Agents; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; N | 2020 |
Effect of nitrate treatment on functional capacity and exercise time in patients with heart failure: a systematic review and meta-analysis.
Topics: Exercise Therapy; Heart Failure; Humans; Nitrates; Quality of Life; Walk Test | 2020 |
Effects of inorganic nitrate supplementation on cardiovascular function and exercise tolerance in heart failure.
Topics: Dietary Supplements; Exercise Tolerance; Heart Failure; Humans; Nitrates; Oxygen Consumption; Stroke | 2021 |
Heart Failure Guidelines on Pharmacotherapy.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2017 |
INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.
Topics: Exercise Test; Exercise Tolerance; Heart Failure; Humans; Nitrates; Randomized Controlled Trials as | 2017 |
Heart Failure with Preserved Ejection Fraction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; D | 2018 |
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
Topics: Angina Pectoris; Animals; Blood Pressure; Contraindications, Drug; Drug Interactions; Erectile Dysfu | 2018 |
Dietary patterns and components to prevent and treat heart failure: a comprehensive review of human studies.
Topics: Antioxidants; Diet, Mediterranean; Dietary Approaches To Stop Hypertension; Dietary Fiber; Feeding B | 2019 |
Dietary nitrate's effects on exercise performance in heart failure with reduced ejection fraction (HFrEF).
Topics: Cardiotonic Agents; Dietary Supplements; Exercise Tolerance; Heart Failure; Humans; Nitrates; Nitric | 2019 |
Nitrates for acute heart failure syndromes.
Topics: Acute Disease; Adult; Heart Failure; Humans; Isosorbide Dinitrate; Nitrates; Nitroglycerin; Randomiz | 2013 |
Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance.
Topics: Angina Pectoris; Delayed-Action Preparations; Drug Interactions; Drug Tolerance; Heart Failure; Huma | 2014 |
Pharmacology and therapeutic role of inorganic nitrite and nitrate in vasodilatation.
Topics: Acute Disease; Animals; Diet; Heart Failure; Humans; Nitrates; Nitric Oxide; Nitrites; Phytochemical | 2014 |
The role of intravenous vasodilators in acute heart failure management.
Topics: Acute Disease; Administration, Intravenous; Atrial Natriuretic Factor; Benzoates; Heart Failure; Hum | 2014 |
Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Mortality; Nitrates; | 2015 |
Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases.
Topics: Animals; Biological Availability; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Di | 2016 |
The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction.
Topics: Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Metabolic Networks and Pathways; Nitrates; | 2016 |
Dietary Nitrate and Skeletal Muscle Contractile Function in Heart Failure.
Topics: Activities of Daily Living; Beta vulgaris; Biological Availability; Dietary Supplements; Fruit and V | 2016 |
Dietary Nitrate and Skeletal Muscle Contractile Function in Heart Failure.
Topics: Activities of Daily Living; Beta vulgaris; Biological Availability; Dietary Supplements; Fruit and V | 2016 |
Dietary Nitrate and Skeletal Muscle Contractile Function in Heart Failure.
Topics: Activities of Daily Living; Beta vulgaris; Biological Availability; Dietary Supplements; Fruit and V | 2016 |
Dietary Nitrate and Skeletal Muscle Contractile Function in Heart Failure.
Topics: Activities of Daily Living; Beta vulgaris; Biological Availability; Dietary Supplements; Fruit and V | 2016 |
Turning Failure into Success: Trials of the Heart Failure Clinical Research Network.
Topics: Diuretics; Double-Blind Method; Enzyme Inhibitors; Heart Failure; Humans; Nitrates; Phosphodiesteras | 2016 |
Guide of Hypertensive Crisis Pharmacotherapy.
Topics: Adrenergic Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Disease Management; Dopam | 2017 |
Rational use of diuretics in acute decompensated heart failure.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Diuretics; Drug Resistance; Drug Therapy, | 2008 |
[Recent findings on nitrates: their action, bioactivation and development of tolerance].
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Coronary Disease; Drug Tolerance; End | 2008 |
Vasodilators in the treatment of acute heart failure: what we know, what we don't.
Topics: Acute Disease; Atrial Natriuretic Factor; Benzoates; Elapid Venoms; Endothelin-1; Heart Failure; Hum | 2009 |
Ivabradine: beyond heart rate control.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzazepines; Calcium Channel Blockers; Cardiovascular | 2009 |
[Organic nitrates: still interesting after all these years].
Topics: Angina Pectoris; Animals; Drug Tolerance; Free Radicals; Heart; Heart Diseases; Heart Failure; Hemod | 2009 |
[Heart failure. 2: Therapy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2010 |
[Cardiovascular disease and sexuality].
Topics: Angina Pectoris; Coitus; Contraindications; Drug Interactions; Female; Heart Failure; Humans; Male; | 2010 |
[Mechanisms and clinical significance of nitrate tolerance].
Topics: Aldehyde Dehydrogenase; Angina Pectoris; Animals; Drug Tolerance; Heart Failure; Humans; Nitrates; O | 2010 |
[Nitrates in cardiology: current role and areas of uncertainty].
Topics: Cardiovascular Diseases; Drug Tolerance; Heart Failure; Humans; Myocardial Ischemia; Nitrates; Pract | 2011 |
[Conservative therapy of patients with stable coronary heart disease].
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Combined Modal | 2012 |
When should we use nitrates in congestive heart failure?
Topics: Cardiotonic Agents; Chronic Disease; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Ni | 2013 |
Diastolic heart failure. Diagnosis, prognosis, treatment.
Topics: Blood Pressure; Diuretics; Heart Failure; Humans; Hypertension; Myocardial Contraction; Nitrates; Pr | 2003 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Buccal nitrates in left ventricular failure.
Topics: Administration, Oral; Evidence-Based Medicine; Heart Failure; Humans; Injections, Intravenous; Nitra | 2003 |
Heart failure in African Americans: pathophysiology and treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Black or African Ame | 2003 |
Nitrates and their use with older people.
Topics: Aged; Angina Pectoris; Heart Failure; Humans; Nitrates | 2004 |
Diastolic heart failure: recognition, diagnosis and management.
Topics: Anti-Arrhythmia Agents; Diastole; Diuretics; Echocardiography; Heart; Heart Failure; Humans; Natriur | 2004 |
[Medical treatment of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Calcium Cha | 2007 |
Redox state, oxidative stress and endothelial dysfunction in heart failure: the puzzle of nitrate-thiol interaction.
Topics: Endothelium, Vascular; Heart Failure; Humans; Nitrates; Nitric Oxide; Oxidation-Reduction; Oxidative | 2007 |
Vasodilators in the management of acute heart failure.
Topics: Acute Disease; Coronary Circulation; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Ki | 2008 |
The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations.
Topics: Acute Disease; Cardiac Output; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Kidney; Milr | 2007 |
Optimal treatment of hypertension with diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2008 |
Drugs and the heart four years on.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Diuret | 1984 |
Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Dr | 1981 |
[New drug preparations used for treating congestive heart failure: converting enzyme inhibitors, nitroprusside, nitrates and calcium channel blockers].
Topics: Calcium Channel Blockers; Captopril; Dose-Response Relationship, Drug; Ferricyanides; Heart Failure; | 1982 |
Vasodilator therapy in chronic congestive heart failure.
Topics: Captopril; Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralaz | 1983 |
Treatment of congestive heart failure.
Topics: Cardiac Glycosides; Diuretics; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Nitrates | 1984 |
The transdermal administration of nitrates: an overview.
Topics: Administration, Oral; Administration, Topical; Angina Pectoris; Blood Pressure; Coronary Disease; Ex | 1983 |
Nitrate delivery systems in perspective. A decade of progress.
Topics: Administration, Intranasal; Administration, Oral; Administration, Topical; Angina Pectoris; Heart Fa | 1984 |
Nitrate tolerance and dependence.
Topics: Ambulatory Care; Angina Pectoris; Animals; Cardiovascular Diseases; Dogs; Drug Tolerance; Heart Fail | 1980 |
Nitroglycerin and long-acting nitrates.
Topics: Administration, Oral; Coronary Circulation; Coronary Disease; Delayed-Action Preparations; Drug Tole | 1980 |
Vasodilator therapy for chronic heart failure.
Topics: Captopril; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglyceri | 1980 |
[Peripheral vasodilator agents in cardiology].
Topics: Clinical Trials as Topic; Coronary Vessels; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocar | 1980 |
Cardiovascular clinical pharmacology of impedance reducing agents.
Topics: Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Phentolamine; Prazosin; | 1981 |
[Peripheral vasodilators in the treatment of heart failure].
Topics: Cardiac Output; Cardiomyopathies; Coronary Circulation; Droperidol; Heart Failure; Humans; Hydralazi | 1982 |
Prevention of remodeling of the heart after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; Clinical Trials | 1995 |
Optimizing the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent | 1994 |
[Chronic left heart ventricle failure and inotropic stimulation].
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cal | 1995 |
Mechanisms of action of nitrates.
Topics: Angina Pectoris; Blood Platelets; Cyclic GMP-Dependent Protein Kinases; Cytochrome P-450 Enzyme Syst | 1994 |
Nitrates and nitrate tolerance in congestive heart failure.
Topics: Animals; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Myocardial Infarction; Neurotransmitte | 1993 |
Mechanisms of nitrate tolerance.
Topics: Angina Pectoris; Animals; Drug Administration Routes; Drug Therapy, Combination; Drug Tolerance; Hea | 1994 |
Nitrates in congestive heart failure.
Topics: Cardiac Output; Drug Tolerance; Exercise; Heart Failure; Hemodynamics; Humans; Muscle, Smooth, Vascu | 1994 |
[Nitrates in heart failure: the hemodynamic effects and clinical implications].
Topics: Cardiovascular Agents; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Nitrates; Time Factors | 1994 |
Nitrates in heart failure.
Topics: Animals; Cardiovascular Agents; Exercise; Heart Failure; Humans; Nitrates | 1994 |
[Nitrates].
Topics: Angina Pectoris; Coronary Artery Disease; Drug Tolerance; Heart Failure; Humans; Myocardial Infarcti | 1993 |
[Vasodilator agents in chronic heart failure: which is the best option?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Clinical Trials as Topic; Drug Therapy, C | 1993 |
[Nitrates in the treatment of congestive heart failure].
Topics: Clinical Trials as Topic; Drug Tolerance; Heart; Heart Failure; Humans; Nitrates | 1993 |
Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Nitrates; Vasodilator Agen | 1993 |
[The use of nitrates in the treatment of heart failure].
Topics: Clinical Trials as Topic; Drug Tolerance; Heart Failure; Humans; Nitrates | 1993 |
Nitric oxide and nitrovasodilators: similarities, differences, and interactions.
Topics: Heart Failure; Humans; Nitrates; Nitric Oxide; Vasodilator Agents | 1996 |
Nitrates in the treatment of congestive heart failure.
Topics: Drug Tolerance; Heart Failure; Hemodynamics; Humans; Mitral Valve Insufficiency; Nitrates | 1996 |
The cardiomyopathy of overload: an unnatural growth response.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Bradykinin; Car | 1995 |
[Cardiac insufficiency: therapeutic aspects in the elderly person].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blocker | 1996 |
[The role of nitrates in therapy of heart failure].
Topics: Heart Failure; Hemodynamics; Humans; Nitrates; Survival Rate; Treatment Outcome; Vasodilator Agents | 1996 |
Is there a role for endothelin in the natural history of heart failure?
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Endothelin Receptor Antagonists; | 1996 |
[Endothelial function, nitrate derivatives and cardiac insufficiency].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Adhesion; Endothelium, Vascular; Heart Failu | 1996 |
[Physiopathologic and pharmacodynamic rationale for the use of nitrate compounds in cardiac decompensation].
Topics: Animals; Coronary Circulation; Heart Failure; Humans; Nitrates; Vasodilation; Vasodilator Agents | 1996 |
[Clinical and diagnostic indications for the use of nitrates in dynamic heart defects (decompensation, left ventricular dysfunction without decompensation, etc].
Topics: Heart Failure; Humans; Nitrates; Vasodilator Agents; Ventricular Dysfunction, Left | 1996 |
[Pharmacologic interactions with nitrates in patients with, or at risk of, cardiac decompensation].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Digitalis Glycosides; Diuretics; | 1996 |
[Effectiveness, tolerance, adverse effects of prolonged therapy with nitrate compounds].
Topics: Drug Tolerance; Heart Failure; Humans; Nitrates; Nitroglycerin; Treatment Outcome; Vasodilator Agent | 1996 |
Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure.
Topics: Angina Pectoris; Angina, Unstable; Heart Failure; Humans; Nitrates; Vasodilator Agents | 1997 |
Oral nitrates: more than symptomatic therapy in coronary artery disease?
Topics: Administration, Oral; Angina Pectoris; Coronary Disease; Drug Therapy, Combination; Heart Failure; H | 1997 |
[Nitric oxide donors in therapy of chronic heart failure].
Topics: Chronic Disease; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Molsidomine; Nitrates; Nitric | 1997 |
[Modification of nitrate tolerance using antioxidants].
Topics: Antioxidants; Ascorbic Acid; Coronary Disease; Drug Tolerance; Free Radicals; Heart Failure; Humans; | 1998 |
[Emergency treatment of acute heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Analgesics, Opioid; Angioplasty, Balloon, Coronary | 1999 |
Treating diastolic failure: the role of diuretics and nitrates.
Topics: Diastole; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Nitrates; Ventricular Dysfunc | 1999 |
[What is the role of nitrates in the treatment of heart decompensation? A rationale for their use].
Topics: Drug Tolerance; Heart Failure; Humans; Nitrates | 1999 |
Acute heart failure: a practical guide to management.
Topics: Acute Disease; Aortic Valve Stenosis; Arrhythmias, Cardiac; Heart Failure; Humans; Mitral Valve Insu | 2000 |
What is the optimal medical management of ischaemic heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2001 |
Nitroglycerin and nitrate esters.
Topics: Angina Pectoris; Animals; Blood Pressure; Cardiac Output; Coronary Circulation; Esters; Heart Failur | 1978 |
[Use of vasodilator agents in circulatory insufficienty].
Topics: Blood Circulation; Dihydralazine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitro | 1979 |
The use of vasodilator agents in the treatment of heart failure.
Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela | 1979 |
Afterload reduction in the management of congestive heart failure following acute myocardial infarction.
Topics: Acute Disease; Dopamine; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Infarction; Ni | 1978 |
Oral vasodilator therapy for chronic heart failure: a plea for caution.
Topics: Cardiac Output; Chronic Disease; Forecasting; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin | 1978 |
Vasodilator therapy of cardiac failure: (first of two parts).
Topics: Blood Vessels; Diuretics; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Hydralazine; Nitrat | 1977 |
Mechanisms of action and efficacy of nitrates in heart failure.
Topics: Forecasting; Heart Failure; Hemodynamics; Humans; Nitrates; Research | 1992 |
Nitrate resistance and tolerance: potential limitations in the treatment of congestive heart failure.
Topics: Drug Administration Schedule; Drug Resistance; Drug Tolerance; Heart Failure; Hemodynamics; Humans; | 1992 |
Effects of nitrates on mortality in acute myocardial infarction and in heart failure.
Topics: Heart Failure; Humans; Myocardial Infarction; Nitrates; Randomized Controlled Trials as Topic | 1992 |
Clinical comparison of nitrates and sydnonimines.
Topics: Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; He | 1991 |
Relationship between the inhibition of receptor-induced increase in cytosolic free calcium concentration and the vasodilator effects of nitrates in patients with congestive heart failure.
Topics: Adult; Blood Platelets; Calcium; Heart Failure; Humans; Isosorbide Dinitrate; Middle Aged; Nifedipin | 1990 |
[Nitrates in the treatment of heart failure].
Topics: Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Isosorbide Dinitrate; Nitrate | 1990 |
[Current status of pharmacology and therapeutic use of nitro derivatives].
Topics: Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Drug Tolerance; Heart Failure; Humans; | 1990 |
[The extension of heart failure therapy with vasodilators].
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Drug Therapy, Combination; Heart | 1990 |
Nitrates are effective in the treatment of chronic congestive heart failure: the protagonist's view.
Topics: Heart Failure; Humans; Nitrates; Physical Exertion | 1990 |
Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint.
Topics: Heart Failure; Humans; Nitrates; Physical Exertion | 1990 |
Congestive heart failure--pathophysiology and medical treatment.
Topics: Autonomic Nervous System; Blood Pressure; Calcium; Cardiomegaly; Cardiotonic Agents; Digitalis; Diur | 1986 |
Nitrates in congestive heart failure.
Topics: Heart Failure; Hemodynamics; Humans; Nitrates; Physical Exertion | 1989 |
The clinical significance of nitrate tolerance in patients with chronic heart failure.
Topics: Drug Tolerance; Heart Failure; Humans; Nitrates | 1989 |
Rationale for treating angina pectoris in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Drug Therapy, Combination; H | 1985 |
Congestive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1986 |
Updated use of digitalis and nitrates in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Coronary Disease; Digitalis Glycosides; | 1988 |
Congestive heart failure.
Topics: Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic | 1986 |
Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration.
Topics: Angina Pectoris; Heart Failure; Humans; Isosorbide Dinitrate; Myocardial Infarction; Nitrates; Nitro | 1987 |
Controversies in the use of transdermal nitroglycerin systems.
Topics: Administration, Topical; Coronary Disease; Dose-Response Relationship, Drug; Heart Failure; Hemodyna | 1987 |
Nitrates.
Topics: Animals; Cardiovascular Diseases; Coronary Disease; Heart Failure; Humans; Nitrates; Nitroglycerin | 1988 |
A reappraisal of nitrate therapy.
Topics: Administration, Cutaneous; Coronary Disease; Drug Tolerance; Heart Failure; Humans; Nitrates; Vasodi | 1988 |
Vasodilators for chronic congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Hydralaz | 1988 |
Use of nitrates in acute and chronic congestive heart failure.
Topics: Acute Disease; Chronic Disease; Heart Failure; Humans; Nitrates | 1987 |
Vasodilator therapy.
Topics: Administration, Oral; Captopril; Cardiac Output; Dose-Response Relationship, Drug; Double-Blind Meth | 1986 |
Effects and development of tolerance using transdermal nitrates in the treatment of congestive heart failure.
Topics: Administration, Cutaneous; Drug Tolerance; Heart Failure; Humans; Nitrates | 1986 |
Development of tolerance to nitrate therapy in chronic congestive heart failure.
Topics: Chronic Disease; Heart Failure; Hemodynamics; Humans; Nitrates | 1986 |
Nitrate therapy in angina and congestive heart failure.
Topics: Angina Pectoris; Coronary Circulation; Heart Failure; Hemodynamics; Humans; Nitrates | 1985 |
Pharmacology of nitroglycerin and long-acting nitrates.
Topics: Absorption; Administration, Oral; Administration, Topical; Angina Pectoris; Animals; Cheek; Delayed- | 1985 |
40 trials available for nitrates and Heart Failure
| Article | Year |
|---|---|
Lifestyle Modification or Medication to Improve Condition of Patients With Asymptomatic Heart Failure - Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization II (MOMOTARO II) Study.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Biomarkers; Diuretics; Female; Heart Failure; Humans | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
The Effect of Dietary Inorganic Nitrate Supplementation on Cardiac Function during Submaximal Exercise in Men with Heart Failure with Reduced Ejection Fraction (HFrEF): A Pilot Study.
Topics: Blood Pressure; Cross-Over Studies; Diet; Dietary Supplements; Double-Blind Method; Echocardiography | 2020 |
Simultaneous Pharmacokinetic Analysis of Nitrate and its Reduced Metabolite, Nitrite, Following Ingestion of Inorganic Nitrate in a Mixed Patient Population.
Topics: Administration, Oral; Aged; Aging; Biological Availability; Body Weight; Cross-Over Studies; Dietary | 2020 |
Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Diuretics; Emergency Service, Hospital; Female; France; Furo | 2020 |
Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Diuretics; Emergency Service, Hospital; Female; France; Furo | 2020 |
Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Diuretics; Emergency Service, Hospital; Female; France; Furo | 2020 |
Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Diuretics; Emergency Service, Hospital; Female; France; Furo | 2020 |
Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Double-Blind Method; Exercise; Exercise Test; Female; Heart Failure; Humans; Male; Middle Aged | 2017 |
Inorganic nitrate as a treatment for acute heart failure: a protocol for a single center, randomized, double-blind, placebo-controlled pilot and feasibility study.
Topics: Acute Disease; Double-Blind Method; Feasibility Studies; Heart Failure; Humans; Nitrates; Nitric Oxi | 2017 |
Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Conv | 2018 |
Effect of organic and inorganic nitrates on cerebrovascular pulsatile power transmission in patients with heart failure and preserved ejection fraction.
Topics: Aged; Aorta; Brain; Carotid Arteries; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged | 2018 |
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heart Fail | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Exer | 2015 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise Tolerance; Fe | 2016 |
Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Dietary nitrate supplementation and exercise tolerance in patients with heart failure with reduced ejection fraction.
Topics: Dietary Supplements; Double-Blind Method; Exercise Test; Exercise Tolerance; Heart Failure; Humans; | 2017 |
BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2009 |
Training-induced increase in nitric oxide metabolites in chronic heart failure and coronary artery disease: an extra benefit of water-based exercises?
Topics: Bicycling; Biomarkers; Catecholamines; Chronic Disease; Coronary Artery Disease; Exercise Therapy; E | 2009 |
Diuretic, opiate and nitrate use in severe acidotic acute cardiogenic pulmonary oedema: analysis from the 3CPO trial.
Topics: Acidosis, Respiratory; Acute Disease; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Diure | 2010 |
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Topics: Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic An | 2010 |
[A role of activation of proinflammatory cytokines and production of autoimmune complexes in the pathogenesis of chronic heart failure in patients with postinfarct cardiac dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antigen-Antibody Compl | 2004 |
Home-based exercise training modulates pro-oxidant substrates in patients with chronic heart failure.
Topics: Adult; Arginine; Cross-Over Studies; Exercise; Female; Heart Failure; Humans; Hypoxanthine; Male; Mi | 2005 |
Echo-Doppler and clinical evaluations to define hemodynamic profile in patients with chronic heart failure: accuracy and influence on therapeutic management.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Hemody | 2005 |
Drugs and the heart. VII. Which drug for which disease?
Topics: Acute Disease; Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Antihypertensiv | 1980 |
[Peripheral vasodilator agents in cardiology].
Topics: Clinical Trials as Topic; Coronary Vessels; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocar | 1980 |
New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure.
Topics: Cardiac Output; Chronic Disease; Coronary Circulation; Dose-Response Relationship, Drug; Drug Tolera | 1983 |
Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure.
Topics: Aged; Arginine; Coronary Disease; Female; Heart Failure; Hemodynamics; Humans; Injections, Intraveno | 1995 |
Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure.
Topics: Biotransformation; Double-Blind Method; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Isosorb | 1994 |
Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group.
Topics: Aged; Death, Sudden, Cardiac; Double-Blind Method; Drug Tolerance; Female; Heart Failure; Humans; Is | 1996 |
Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure.
Topics: Administration, Cutaneous; Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor | 1998 |
Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure.
Topics: Acetylcholine; Enzyme Inhibitors; Female; Forearm; Heart Failure; Hemodynamics; Humans; Male; Middle | 1998 |
Endogenous nitric oxide in patients with chronic heart failure (CHF): relation to functional impairment and nitrate-containing therapies.
Topics: Blood Gas Analysis; Breath Tests; Cardiac Catheterization; Chronic Disease; Exercise Test; Female; H | 2000 |
Transient improvement of acetylcholine responses after short-term oral L-arginine in forearms of human heart failure.
Topics: Acetylcholine; Administration, Oral; Adult; Analysis of Variance; Arginine; Blood Pressure; Cross-Ov | 2000 |
[Ultrasonography of the inferior vena cava (IVC) in the diagnosis and monitoring of therapy in patients with chronic congestive heart failure].
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Body Weight; Calcium Chann | 2001 |
Chronic use of continuous dosing of long-term nitrates does not prevent cardiac events in patients with severe acute myocardial infarction.
Topics: Acute Disease; Aged; Death, Sudden, Cardiac; Female; Heart Failure; Humans; Male; Middle Aged; Myoca | 2000 |
Is the use of long acting nitrates beneficial in the patient with angina pectoris? (The positive side).
Topics: Administration, Oral; Angina Pectoris; Biological Availability; Blood Pressure; Cardiac Output; Clin | 1977 |
Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition.
Topics: Age Factors; Captopril; Cardiac Output, Low; Cause of Death; Coronary Disease; Digitalis Glycosides; | 1991 |
[Pharmacological correction by roxicam of the prostacyclin-thromboxane system in acute myocardial infarction complicated by heart failure].
Topics: 6-Ketoprostaglandin F1 alpha; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Glycosides; | 1991 |
[Development and status of nitrate therapy in East Germany].
Topics: Angina Pectoris; Delayed-Action Preparations; Dose-Response Relationship, Drug; Germany, East; Heart | 1989 |
Aspects on "traditional" vasodilators in the treatment of chronic heart failure.
Topics: Cardiac Output; Clinical Trials as Topic; Double-Blind Method; Heart; Heart Failure; Hemodynamics; H | 1986 |
Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure.
Topics: Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Electrocard | 1985 |
177 other studies available for nitrates and Heart Failure
| Article | Year |
|---|---|
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonis | 2022 |
Association of serum nitric oxide metabolite level with mortality in patients undergoing coronary angiography.
Topics: Aged; Biomarkers; C-Reactive Protein; Coronary Angiography; Heart Failure; Humans; Middle Aged; Natr | 2022 |
Prevalence, risk factors, and survival associated with pulmonary hypertension and heart failure among patients with underlying coronary artery disease: a national prospective, multicenter registry study in China.
Topics: Coronary Artery Disease; Creatinine; Heart Failure; Humans; Hypertension, Pulmonary; Nitrates; Preva | 2022 |
Inpatient Quality-of-Care Measures for Heart Failure: Treatment Gaps and Opportunities in the Contemporary Era.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2022 |
Impact of prehospital IV furosemide or nitrate application on hospital outcome in acute heart failure patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Diuretics; Emergency Medical Services; Furosemide; Heart Fai | 2022 |
Association of Urinary Nitrate With Diabetes Complication and Disease-Specific Mortality Among Adults With Hyperglycemia.
Topics: Adult; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; H | 2023 |
[Epidemiological and prognostic profile of acute heart failure: experience in the emergency department at the Charles Nicole Hospital of Tunis from 2013 to 2014].
Topics: Acute Coronary Syndrome; Acute Disease; Adult; Aged; Aged, 80 and over; Continuous Positive Airway P | 2019 |
Gender Differences in Long-Term Outcomes of Medical Therapy and Successful Percutaneous Coronary Intervention for Coronary Chronic Total Occlusions.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; China; Coronary Occlusion; Female; Follow-Up Studies | 2019 |
Do nitrates improve survival on acute heart failure?
Topics: Administration, Intravenous; Heart Failure; Humans; Hypertension; Nitrates; Vasodilator Agents | 2020 |
High-dose intravenous nitrates in acute heart failure: Level of evidence and adherence.
Topics: Heart Failure; Humans; Hypertension; Nitrates | 2020 |
The authors respond.
Topics: Heart Failure; Humans; Hypertension; Nitrates | 2020 |
Endothelial-specific overexpression of cationic amino acid transporter-1 prevents loss of kidney function in heart failure.
Topics: Animals; Blood Pressure; Body Weight; Cardiomyopathy, Dilated; Cationic Amino Acid Transporter 1; En | 2020 |
Sex Differences in Clinical Characteristics and 2-Year Prognosis of Patients with Heart Failure Grouped by Left Ventricular Ejection Fraction Status.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angiotensin Receptor Antagon | 2020 |
Higher urinary nitrate was associated with lower prevalence of congestive heart failure: results from NHANES.
Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Female; Heart Failure; Humans; Male; Middle Aged; | 2020 |
Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?
Topics: Heart Failure; Humans; Nitrates; Nitric Oxide; Nitrites; Stroke Volume | 2021 |
Vericiguat, organic nitrates, and heart failure in African Americans.
Topics: Black or African American; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hydralazine; Isoso | 2021 |
Inorganic nitrate attenuates cardiac dysfunction: roles for xanthine oxidoreductase and nitric oxide.
Topics: Animals; Cardiomegaly; Case-Control Studies; Clinical Studies as Topic; Disease Models, Animal; Fibr | 2022 |
Inorganic Nitrates:
Topics: Exercise Tolerance; Heart Failure; Humans; Nitrates; Qi; Stroke Volume | 2017 |
Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Disease Progression; Drug Therapy, Combination; Female; Heart Failure; Hosp | 2017 |
Effects of supervised exercise and dietary nitrate in older adults with controlled hypertension and/or heart failure with preserved ejection fraction.
Topics: Aged; Beta vulgaris; Blood Pressure; Dietary Supplements; Exercise; Female; Fruit and Vegetable Juic | 2017 |
Cardiovascular assessment for non-cardiac surgery: European guidelines.
Topics: Adrenergic beta-Antagonists; Anesthesiology; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2017 |
Inorganic vs. organic nitrates for heart failure with preserved ejection fraction: it's not all in your head!
Topics: Heart Failure; Humans; Nitrates; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, | 2017 |
The Nitrate-Nitrite-NO Pathway as a Novel Therapeutic Target in Heart Failure with Reduced Ejection Fraction.
Topics: Heart Failure; Humans; Nitrates; Nitrites; Stroke Volume; Ventricular Dysfunction, Left | 2018 |
Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure: Insight from a nationwide claim-based database.
Topics: Acute Disease; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Facto | 2019 |
Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Middle Aged; Nitra | 2019 |
Use of Nitrates and Risk of Cardiovascular Events in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarc | 2019 |
Relationship between drug application and mortality rate in Chinese older coronary artery disease/chronic heart failure patients with and without low glomerular filtration rate.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2019 |
A novel spectrophotometric method for indirect determination of nitric oxide (NO) in serum.
Topics: Adult; Aged; Cadmium; Case-Control Studies; Copper; Edetic Acid; Female; Heart Failure; Humans; Male | 2013 |
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Angiotensin Receptor Antagonists; Angiotensin-Co | 2013 |
Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies.
Topics: Acute Disease; Aged; Analgesics, Opioid; Blood Pressure; Cardiotonic Agents; Chronic Disease; Diseas | 2013 |
Intravenous therapies in acute heart failure–lack of effect or lack of well powered studies?
Topics: Analgesics, Opioid; Diuretics; Heart Failure; Humans; Infusions, Intravenous; Morphine; Nitrates | 2014 |
Nitrate therapy for heart failure: benefits and strategies to overcome tolerance.
Topics: Drug Tolerance; Heart Failure; Humans; Hydralazine; Nitrates; Vasodilator Agents | 2013 |
Do Intravenous Nitrates Improve Dyspnea in Acute Heart Failure Syndromes More Than Alternative Pharmacologic Interventions?
Topics: Heart Failure; Humans; Nitrates; Vasodilator Agents | 2015 |
Harnessing the nitrate-nitrite-nitric oxide pathway for therapy of heart failure with preserved ejection fraction.
Topics: Animals; Blood Pressure; Exercise Test; Exercise Tolerance; Female; Heart Failure; Humans; Male; Mus | 2015 |
Influence of Intravenous Nitrate Treatment on Early Mortality Among Patients With Acute Heart Failure. NITRO-EAHFE Study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Emergency Service, Hospital; Female; Heart Failure; Humans; | 2015 |
Underutilization of IV nitrates in the treatment of acute heart failure.
Topics: Acute Disease; Administration, Intravenous; Aged; Aged, 80 and over; Comorbidity; Drug Utilization R | 2015 |
Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2015 |
Impact of Nitrate Use on Survival in Acute Heart Failure: A Propensity-Matched Analysis.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiology Service, Hospital; Cardiovascular Agents; Chi-Squ | 2016 |
Impact of Chronic Nitrate Therapy in Patients With Ischemic Heart Failure.
Topics: Aged; Chi-Square Distribution; Drug Administration Schedule; Female; Heart Failure; Humans; Kaplan-M | 2016 |
Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients - Multiple biomarkers prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Female; Follow-Up Studies; Heart Failure | 2016 |
Cardiac aging and the fountain of youth.
Topics: Adolescent; Heart; Heart Failure; Humans; Nitrates; Nitric Oxide | 2016 |
Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and o | 2016 |
Where's the "Label" for Beet Juice: The Value of the Food and Drug Administration.
Topics: Beta vulgaris; Heart Failure; Humans; Nitrates; United States Food and Drug Administration | 2016 |
Oral nitrate and citrulline decrease blood pressure and increase vascular conductance in young adults: a potential therapy for heart failure.
Topics: Administration, Oral; Blood Flow Velocity; Blood Pressure; Cardiotonic Agents; Citrulline; Dietary S | 2016 |
Dietary nitrate supplementation: impact on skeletal muscle vascular control in exercising rats with chronic heart failure.
Topics: Administration, Oral; Animals; Blood Flow Velocity; Chronic Disease; Dietary Supplements; Exercise T | 2016 |
INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2016 |
Heart failure in patients presenting with dyspnoea to the emergency department in the Asia Pacific region: an observational study.
Topics: Adult; Aged; Asia; Australia; Diuretics; Dyspnea; Emergency Service, Hospital; Female; Heart Failure | 2017 |
Nonselective ETA/ETB-receptor blockade increases systemic blood pressure of Bio 14.6 cardiomyopathic hamsters.
Topics: Animals; Atrasentan; Blood Pressure; Cardiomyopathies; Cricetinae; Endothelin A Receptor Antagonists | 2008 |
Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study.
Topics: Acute Disease; Administration, Cutaneous; Administration, Sublingual; Adult; Aged; Aged, 80 and over | 2010 |
Serial measurements of high sensitive cardiac troponin I in patients with acutely decompensated heart failure treated with carperitide or nitrates.
Topics: Aged; Atrial Natriuretic Factor; Blood Pressure; Female; Heart Failure; Humans; Male; Nitrates; Trop | 2010 |
Neonatal asphyxia induces the nitration of cardiac myosin light chain 2 that is associated with cardiac systolic dysfunction.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Blotting, Western; Cardiac Myosins; Electrophoresis, | 2010 |
Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation.
Topics: Animals; Arginase; Arginine; Blotting, Western; Cardiac Pacing, Artificial; Disease Models, Animal; | 2010 |
In-vivo nitric oxide synthesis is reduced in obese patients with metabolic syndrome: application of a novel stable isotopic method.
Topics: Adult; Case-Control Studies; Comorbidity; Diabetes Mellitus, Type 2; Diagnostic Tests, Routine; Fema | 2011 |
In-vivo nitric oxide synthesis is reduced in obese patients with metabolic syndrome: application of a novel stable isotopic method.
Topics: Adult; Case-Control Studies; Comorbidity; Diabetes Mellitus, Type 2; Diagnostic Tests, Routine; Fema | 2011 |
In-vivo nitric oxide synthesis is reduced in obese patients with metabolic syndrome: application of a novel stable isotopic method.
Topics: Adult; Case-Control Studies; Comorbidity; Diabetes Mellitus, Type 2; Diagnostic Tests, Routine; Fema | 2011 |
In-vivo nitric oxide synthesis is reduced in obese patients with metabolic syndrome: application of a novel stable isotopic method.
Topics: Adult; Case-Control Studies; Comorbidity; Diabetes Mellitus, Type 2; Diagnostic Tests, Routine; Fema | 2011 |
Natural history of end-stage LV dysfunction: has it improved from the classic Franciosa and Cohn Graph?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiac Resynch | 2011 |
Subtotal nephrectomy plus coronary ligation leads to more pronounced damage in both organs than either nephrectomy or coronary ligation.
Topics: Animals; Blood Pressure; Cardio-Renal Syndrome; Coronary Stenosis; Disease Models, Animal; Gene Expr | 2012 |
Improvement in refractory heart failure by nephrectomy for renal tumour.
Topics: Blood Transfusion; Diagnosis, Differential; Diuretics; Echocardiography; Heart Failure; Humans; Kidn | 2012 |
Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide.
Topics: Adult; Aged; Arm; Cardiomyopathy, Dilated; Case-Control Studies; Female; Heart Failure; Heart Functi | 2002 |
Patterns of pharmacotherapy in patients hospitalised for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Aspirin | 2003 |
CYANOSIS IN THE NEW-BORN.
Topics: Aniline Compounds; Birth Injuries; Brain Diseases; Chlorine; Cyanosis; Heart Defects, Congenital; He | 1964 |
Reversal of heart failure remodeling: is it maintained?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Cardiomyopathies; Echocardiography; Female | 2003 |
A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Cardiomyopathy, Dilated; Cricetinae; Cytos | 2004 |
Epidemiological and pharmacological profile of congestive heart failure at Turkish academic hospitals.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2004 |
A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting Enzyme | 2004 |
Survey of the use of organic nitrates for the treatment of chronic congestive heart failure in the United States.
Topics: Chronic Disease; Exercise Tolerance; Health Care Surveys; Heart Failure; Hemodynamics; Humans; Nitra | 2004 |
Heart failure increases protein expression and enzymatic activity of heme oxygenase-1 in the lung.
Topics: Animals; Blotting, Western; Cyclic GMP; Heart Failure; Heme Oxygenase (Decyclizing); Heme Oxygenase- | 2005 |
Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Angiotensin-Converting Enzyme | 2005 |
Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2005 |
Heart failure guidelines and prescribing in primary care across Europe.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anticoag | 2005 |
Report from the Cardiovascular and Renal Drugs Advisory Committee: US Food and Drug Administration; June 15-16, 2005; Gaithersburg, Md.
Topics: Antihypertensive Agents; Black People; Cardiovascular Agents; Drug Combinations; Drug Labeling; Epid | 2005 |
Statins associated with reduced mortality in patients admitted for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Case-Control Studies; Diabetes Mellitus; Female; Heart Failure; H | 2006 |
'Can I come off the tablets now?' A qualitative analysis of heart failure patients' understanding of their medication.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 2006 |
Drugs and the heart. II. Nitrates.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Coronary Circulation; Drug Therapy, Co | 1980 |
Drugs and the heart. VI. Vasodilating drugs.
Topics: Cardiotonic Agents; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Hypertension; | 1980 |
Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death.
Topics: Adrenergic beta-Antagonists; Cardiac Catheterization; Cardiovascular Diseases; Coronary Disease; Hea | 1980 |
[How can left ventricular function be modified?].
Topics: Adrenergic alpha-Antagonists; Cardiac Surgical Procedures; Diet, Sodium-Restricted; Digitalis Glycos | 1982 |
Nifedipine therapy in angina pectoris: evaluation of safety and side effects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel | 1982 |
[The use of vasodilator agents in the therapy of chronic cardiac insufficiency].
Topics: Adrenergic alpha-Antagonists; Calcium Channel Blockers; Captopril; Clonidine; Diuretics; Heart Failu | 1982 |
[Frequent errors in the therapy of heart disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biologic | 1982 |
[Current problems of the treatment of circulatory insufficiency].
Topics: Adrenergic beta-Agonists; Digitalis Glycosides; Drug Evaluation; Heart Failure; Humans; Nitrates; Ph | 1983 |
Practical guidelines for treatment with beta-blockers and nitrates in patients with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Coronary Disease; Diuretics; Drug Therapy, Combination; Heart Failure; | 1983 |
Rational medical therapy for stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Heart | 1984 |
[Therapy of angina pectoris].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Calcium Ch | 1984 |
[Diagnosis and drug therapy in the postinfarct phase].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium | 1984 |
[Alternatives to digitalis therapy?].
Topics: Albuterol; Captopril; Dobutamine; Dopamine; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; | 1981 |
[Alternatives to digitalis therapy].
Topics: Aminopyridines; Amrinone; Captopril; Catecholamines; Diuretics; Heart Failure; Humans; Hydralazine; | 1983 |
Vasodilators for chronic congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Vasodilator Agents | 1984 |
Nitroglycerin and long-acting nitrates in clinical practice.
Topics: Angina Pectoris; Angina Pectoris, Variant; Coronary Vasospasm; Drug Tolerance; Heart Failure; Humans | 1983 |
Mechanism of action of nitrates. Role of changes in venous capacitance and in the left ventricular diastolic pressure-volume relation.
Topics: Animals; Cardiac Output; Coronary Circulation; Dogs; Heart Failure; Humans; Nitrates; Nitroglycerin; | 1984 |
Nitrates in heart failure. Pathophysiological mechanisms and therapeutic applications.
Topics: Cardiac Output; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorb | 1984 |
Nitrates in heart disease.
Topics: Angina Pectoris; Heart Diseases; Heart Failure; Humans; Nitrates; Vasodilator Agents | 1984 |
[Changes in the indices of external respiration and central hemodynamics during the use of nitrates in the therapy of chronic heart failure].
Topics: Adult; Cardiac Glycosides; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Hemody | 1984 |
[Therapy of cardiac insufficiency: vasodilator agents].
Topics: Captopril; Heart Failure; Humans; Nitrates; Phentolamine; Prazosin; Vasodilator Agents | 1982 |
Hemodynamic effects of nitrates in chronic heart failure and myocardial infarction.
Topics: Chronic Disease; Heart Failure; Hemodynamics; Humans; Isosorbide Dinitrate; Myocardial Infarction; N | 1980 |
[Long-acting nitrate compounds (author's transl)].
Topics: Delayed-Action Preparations; Heart Failure; Humans; Kinetics; Nitrates; Nitroglycerin; Vasodilator A | 1980 |
Nitrate tolerance and dependence. A critical assessment.
Topics: Angina Pectoris; Animals; Dogs; Drug Tolerance; Heart Failure; Humans; Isosorbide Dinitrate; Nitrate | 1980 |
Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.
Topics: Blood Pressure; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heart Rate; Hem | 1981 |
[Use of nitrates in clinical practice].
Topics: Angina Pectoris; Cardiovascular System; Electrocardiography; Heart Failure; Humans; Myocardial Infar | 1980 |
Nitrates, package inserts, and the Food and Drug Administration. A clinical paradox.
Topics: Angina Pectoris; Biological Availability; Delayed-Action Preparations; Drug Labeling; Heart Failure; | 1981 |
Enhancement of phentolamine by nitrates in patients with congestive heart failure.
Topics: Blood Pressure; Cardiac Output; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans | 1981 |
The nitrites and nitrates.
Topics: Angina Pectoris; Angina Pectoris, Variant; Drug Interactions; Ethanol; Heart Failure; Liver; Mouth F | 1982 |
Preload and afterload without anguish: a simplified framework.
Topics: Cardiac Output; Coronary Circulation; Heart Failure; Heart Function Tests; Humans; Hydralazine; Nitr | 1982 |
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N | 1983 |
Tolerance to organic nitrates: clinical and experimental perspectives.
Topics: Angina Pectoris; Animals; Dogs; Dose-Response Relationship, Drug; Drug Tolerance; Heart Failure; Hem | 1983 |
Hydralazine in chronic CHF.
Topics: Administration, Oral; Aortic Valve Insufficiency; Cardiac Output; Chronic Disease; Drug Therapy, Com | 1981 |
[Differential therapy of heart insufficiency].
Topics: Chronic Disease; Digitalis; Dihydralazine; Heart Failure; Humans; Nitrates; Plants, Medicinal; Plant | 1982 |
The longer term efficacy of vasodilators in heart failure.
Topics: Arteries; Heart Failure; Humans; Hydralazine; Nitrates; Vasodilator Agents; Veins | 1982 |
[High-dose nitrate therapy in angina pectoris and cardiac insufficiency].
Topics: Angina Pectoris; Dose-Response Relationship, Drug; Heart Failure; Humans; Nitrates; Oxygen Consumpti | 1982 |
[Do fixed combinations of digoxin and nitrates have a therapeutic advantage?].
Topics: Coronary Disease; Digoxin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heart Failur | 1981 |
[Treatment with nitrate depot preparations and calcium antagonists].
Topics: Angina Pectoris; Calcium; Delayed-Action Preparations; Heart Failure; Humans; Nitrates | 1981 |
[Heart insufficiency: current aspects of physiopathology and therapy].
Topics: Cardiac Output; Cardiotonic Agents; Echocardiography; Heart Failure; Hemodynamics; Humans; Myocardia | 1981 |
[Acute and chronic treatment of chronic cardiac insufficiency with nitrates or prazosin respectively].
Topics: Acute Disease; Chronic Disease; Heart Failure; Humans; Nitrates; Prazosin; Quinazolines | 1981 |
New approaches to therapy of acute heart failure.
Topics: Antihypertensive Agents; Dobutamine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroprusside; Ox | 1980 |
Vasodilator therapy of chronic congestive heart failure.
Topics: Ambulatory Care; Chronic Disease; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Quinazolin | 1980 |
Raised nitrate concentrations in chronic heart disease.
Topics: Amino Acid Oxidoreductases; Chronic Disease; Heart Failure; Humans; NADPH Dehydrogenase; Nitrates; N | 1994 |
Nitric oxide production and heart failure.
Topics: Arginine; Heart Failure; Humans; Nitrates; Nitric Oxide; omega-N-Methylarginine; Vascular Resistance | 1995 |
Increased nitric oxide production in heart failure.
Topics: Aged; Cardiomyopathy, Dilated; Female; Heart Failure; Heart Function Tests; Humans; Male; Middle Age | 1994 |
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Digoxin; Heart Failure; Humans; Nitrates | 1993 |
Frusemide or nitrates for acute heart failure?
Topics: Acute Disease; Administration, Sublingual; Diuretics; Furosemide; Heart Failure; Hemodynamics; Human | 1996 |
[Refractory heart failure: it requires the use of polychemotherapy. What is the rationale?].
Topics: Adrenergic Agonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomy | 1995 |
[Cardiac insufficiency. Which therapeutic possibilities have long-term results].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Combination; Heart Failure; Human | 1992 |
[The nitrates in cardiac decompensation].
Topics: Heart Failure; Humans; Nitrates; Vasodilator Agents | 1996 |
Endogenous nitric oxide production and atrial natriuretic peptide biological activity in infants undergoing cardiac operations.
Topics: Atrial Natriuretic Factor; Blood Pressure; Cardiopulmonary Bypass; Cyclic GMP; Heart Failure; Heart | 1997 |
Age-dependent augmentation of cardiac endothelial NOS in a genetic rat model of heart failure.
Topics: Aging; Animals; Endothelium, Vascular; Heart; Heart Failure; Heart Ventricles; Male; Nitrates; Nitri | 1997 |
Mechanisms of nitrate accumulation in plasma during pacing-induced heart failure in conscious dogs.
Topics: Acetylcholine; Animals; Blood Pressure; Bradykinin; Carbon Dioxide; Cardiac Pacing, Artificial; Coro | 1997 |
The metabolic fate of long-term inhaled nitric oxide.
Topics: Administration, Inhalation; Adult; Aged; Cardiac Surgical Procedures; Drug Monitoring; Female; Heart | 1998 |
Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure.
Topics: Animals; Blotting, Western; Cardiac Pacing, Artificial; Creatinine; Densitometry; Dogs; Heart Atria; | 1998 |
Effects of endotoxin on human myocardial contractility involvement of nitric oxide and peroxynitrite.
Topics: Adult; Culture Techniques; Dose-Response Relationship, Drug; Endotoxins; Female; Heart Failure; Huma | 1999 |
Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure.
Topics: Adult; Aged; Arginine; Cardiomyopathies; Creatinine; Exercise Test; Female; Heart Failure; Humans; L | 1999 |
To trust or not to trust.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coron | 1999 |
[Hypertensive heart disease with left ventricular diastolic dysfunction demonstrating restrictive hemodynamics: a case report].
Topics: Atrial Natriuretic Factor; Calcium Channel Blockers; Coronary Circulation; Diastole; Diuretics; Echo | 1999 |
Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Endothelium, Vascular; Gene Expression Regulation; Guanylat | 1999 |
Effects of L-arginine on endothelial and cardiac function in rats with heart failure.
Topics: Animals; Aorta, Thoracic; Arginine; Endothelium, Vascular; Heart; Heart Failure; Hemodynamics; Male; | 1999 |
Exhaled nitric oxide during incremental and constant workload exercise in chronic cardiac failure.
Topics: Aged; Exercise; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Nitrate | 2000 |
Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Animals; Electron Spin Resonance Spectroscop | 2000 |
Nitric oxide synthesis and congestive heart failure.
Topics: Heart Failure; Humans; Nitrates; Nitric Oxide | 2000 |
Plasma nitrate accumulation during the development of pacing-induced dilated cardiac myopathy in conscious dogs is due to renal impairment.
Topics: Animals; Ascites; Cachexia; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated; Consciousness; Crea | 2001 |
Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure.
Topics: Animals; Creatine Kinase; Creatine Kinase, MM Form; Heart Failure; Image Processing, Computer-Assist | 2001 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Frusemide or nitrates in acute left ventricular failure.
Topics: Aged; Aged, 80 and over; Evidence-Based Medicine; Furosemide; Heart Failure; Humans; Male; Nitrates; | 2001 |
Nitric oxide and peroxynitrite: the balance between cardioprotection and cardiotoxicity.
Topics: Animals; Coronary Circulation; Cytokines; Heart Failure; Heart Rate; Humans; Myocardial Contraction; | 2001 |
Nitric oxide and cardiac parasympathetic control in human heart failure.
Topics: Adult; Aged; Baroreflex; Blood Pressure; Cardiotonic Agents; Cross-Over Studies; Enzyme Inhibitors; | 2002 |
Treatment of congestive heart failure.
Topics: Angioedema; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hydrala | 2002 |
Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure.
Topics: Animals; Blotting, Western; Coronary Vessels; Disease Models, Animal; Enzyme Inhibitors; Heart Failu | 2002 |
Treatments for heart-failure: stimulation or unloading ?
Topics: Heart Failure; Humans; Hydralazine; Myocardial Contraction; Nitrates; Phentolamine; Stimulation, Che | 1979 |
[2. International Symposium on Nitrates; Berlin 1-3 June 1978. Nitrate-effect on the heart and circulation].
Topics: Angina Pectoris; Animals; Blood Circulation; Coronary Disease; Heart; Heart Failure; Humans; Isosorb | 1978 |
[Peroral nitrate therapy in severe cardiac insufficiency following acute myocardial infarct].
Topics: Administration, Oral; Aged; Delayed-Action Preparations; Heart Failure; Humans; Isosorbide Dinitrate | 1978 |
[Vasodilator therapy of heart failure].
Topics: Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Prazosin; Stroke Volume; | 1979 |
Clinical use of nitrates. II. Nitrates in congestive heart failure.
Topics: Administration, Oral; Drug Evaluation; Heart Failure; Humans; Nitrates; Nitroglycerin; Ointments; Su | 1979 |
Nonparenteral vasodilator therapy for chronic congestive heart failure.
Topics: Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglycerin; Prazosin; Vasodilator Age | 1979 |
Changing concepts in the management of congestive cardiac failure and acute myocardial infarction.
Topics: Heart Failure; Hospitalization; Humans; Length of Stay; Myocardial Infarction; Nitrates; Nitroglycer | 1979 |
Clinical indicators of left main coronary artery disease in unstable angina.
Topics: Angina Pectoris; Angiography; Anticoagulants; Calcinosis; Cardiac Catheterization; Cardiomegaly; Col | 1979 |
Management of sudden coronary death.
Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Artery Bypass; Coronary Disease; Death, Sudden; Female; | 1977 |
Afterload reduction in congestive heart failure.
Topics: Dopamine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Phentolamine; | 1978 |
[Nitrates and other peripheral vasodilator agents in acute myocardial infarct and congestive heart failure].
Topics: Acute Disease; Heart Failure; Hemodynamics; Humans; Myocardial Infarction; Nitrates; Nitroglycerin; | 1978 |
Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
Topics: Chronic Disease; Dobutamine; Dopamine; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; Moni | 1979 |
[Hemodynamic consequences of the furosemide treatment of cardiac insufficiency in recent myocardial infarct].
Topics: Aged; Diuresis; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardi | 1979 |
Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure.
Topics: Adolescent; Aged; Cardiac Output; Chronic Disease; Heart Failure; Heart Ventricles; Hemodynamics; Hu | 1978 |
Outflow resistance as a regulator of left ventricular performance.
Topics: Blood Pressure; Cardiac Output; Heart Failure; Heart Rate; Heart Ventricles; Hemodynamics; Humans; H | 1978 |
Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure.
Topics: Blood Pressure; Cardiac Output; Delayed-Action Preparations; Heart Failure; Heart Rate; Heart Ventri | 1978 |
[Isotope study of the effects of a nitrate derivative on pulmonary blood volume. Application in the treatment of cardiogenic pulmonary edema].
Topics: Aged; Blood Pressure; Blood Volume; Capillary Resistance; Depression, Chemical; Heart Failure; Heart | 1976 |
Differences in blood pressure regulation of congestive heart failure, before and after treatment, correlate with changes in the circulating pattern of atrial natriuretic peptide.
Topics: Aged; Atrial Natriuretic Factor; Blood Pressure; Cardiotonic Agents; Digoxin; Drug Therapy, Combinat | 1992 |
[Pharmacological treatment of heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Digitalis Glycosides; Diuretics; Hea | 1992 |
International experience with nitrates.
Topics: Coronary Disease; Heart Failure; Humans; Nitrates | 1991 |
Acute heart failure: determinants of outcome.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Digoxin; Diuretics; Female; Follow-Up Studi | 1991 |
Abnormal baroreflex control of heart rate in decompensated congestive heart failure and reversal after compensation.
Topics: Adaptation, Physiological; Adult; Atropine; Electrocardiography; Female; Heart Failure; Heart Rate; | 1991 |
[Therapeutic tolerance with derivative nitrates].
Topics: Angina Pectoris; Animals; Drug Tolerance; Heart Failure; Humans; Nitrates; Nitroglycerin | 1989 |
Regional blood flow responses to vasodilators and inotropes in congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Circulation; | 1988 |
[Nitrates in the combined treatment of congestive heart failure patients in a mountainous location].
Topics: Adolescent; Adult; Altitude; Digoxin; Drug Evaluation; Drug Therapy, Combination; Female; Heart Fail | 1986 |
The role of transdermal nitroglycerin in the treatment of coronary heart disease.
Topics: Administration, Topical; Coronary Disease; Heart; Heart Failure; Humans; Muscle, Smooth, Vascular; N | 1986 |
Nitrates: the problem of tolerance.
Topics: Angina Pectoris; Drug Tolerance; Heart Failure; Humans; Isosorbide Dinitrate; Nitrates; Nitroglyceri | 1988 |
[Use of delayed-action nitrate preparations in the treatment of heart failure].
Topics: Aged; Chronic Disease; Delayed-Action Preparations; Female; Heart Failure; Humans; Male; Middle Aged | 1987 |
[Nitrates: clinical pharmacology and therapeutic uses].
Topics: Animals; Chemical Phenomena; Chemistry; Coronary Circulation; Coronary Disease; Drug Administration | 1986 |
[Nitrate derivatives. Pharmacology].
Topics: Angina Pectoris; Blood Pressure; Heart Failure; Hemodynamics; Humans; Nitrates | 1985 |
[Significance of nitrates in acute therapy of heart failure with and without lung edema].
Topics: Cardiac Output, Low; Cardiomyopathy, Dilated; Dobutamine; Drug Therapy, Combination; Heart Failure; | 1985 |
Vasodilator therapy for chronic congestive heart failure.
Topics: Captopril; Cardiac Catheterization; Heart Failure; Hospitalization; Humans; Hydralazine; Myocardial | 1985 |
[Hemodynamic aspects of differential therapy of acute myocardial infarct with nitrates].
Topics: Angina Pectoris; Blood Pressure; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Infusions, P | 1985 |
Nitrates for congestive heart failure.
Topics: Drug Therapy, Combination; Exercise Test; Heart Failure; Hemodynamics; Humans; Nitrates; Time Factor | 1985 |
[Conservative therapy of angina pectoris].
Topics: Acute Disease; Amyl Nitrite; Angina Pectoris; Anticoagulants; Coronary Disease; Digitalis Glycosides | 1970 |